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Abstract 
A new HPLC method that is based on zwitterionic hydrophilic interaction liquid 
chromatography (ZIC-HILIC) coupled with ultraviolet detection was developed, optimized  
and validated for simultaneous determination of Amprolium hydrochloride , 
Sulfaquinoxaline Sodium , and Vitamin K3 (as menadione sodium bisulfite) in A.S.K 
Powder. The separation was carried out using ZIC-HILIC column (250 mm×4.6 mm, 5 µm) 
and a mobile phase of 0.2 M Ammonium acetate (NH4AC) buffer and acetonitrile (ACN)  
(15:85; v/v) with pH adjusted to 5.7 by glacial acetic acid (G.A.A) at a flow rate of 0.5 
ml/min.  The analytes were monitored by UV detection at 263 nm.  
The effects of the operational chromatographic conditions on the separation and column 
efficiency were thoroughly investigated, including the concentration of the organic solvent 
(ACN) in the aqueous-organic mobile phase, the ionic strength of the NH4AC buffer and 
pH of the mobile phase.  
The optimized method was finally subjected to full analytical validation by examining 
specificity, accuracy, precision, linearity, range, ruggedness, robustness and stress 
conditions. The results were evaluated according to the International Conference on 
Harmonization (ICH) and United States Pharmacopoeia (USP33/NF28) guidelines and the 
method fulfilled validation criteria. In addition, the assay was shown to indicate stability 
and can be used to analyze for degradation products; for example; sulfaquinoxaline 
impurity A. 
The developed method is sensitive, specific, fast, accurate and requires minimum sample 
manipulation. The analysis time requires only 18 minutes. The new optimized HPLC 
method was applied on three commercial A.S.K batches for analysis of amprolium 
hydrochloride, sulfaquinoxaline sodium and vitamin K3. All the active ingredients were 
separated from excipients according to the authentic specifications.  
Key words: Amprolium, Sulfaquinoxaline, Menadione sodium bisulfite, A.S.K Powder, 
ZIC-HILIC, validation, Stability-indicating. 
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Chapter One                    
_________________________________________________________________________ 
Introduction 
 ______________________________________________________________ 
 
1.1 General Introduction 
 
The three combined active pharmaceutical components to be separated and analyzed are 
mainly used for the treatment and control of coccidiosis. 
  
"Coccidiosis is an acute invasion and destruction of intestinal mucosa by protozoa of the 
genera Eimeria or Isospora. Infection is characterized by diarrhea, fever, inappetence, weight 
loss, emaciation, and sometimes death. Coccidiosis is a serious disease in cattle, sheep, goats, 
pigs, poultry, and also rabbits, in which the liver as well as the intestine can be affected. In 
dogs, cats, and horses, it is less often diagnosed but can result in clinical illness". [1]  
 
Coccidiasis is the infection of animals with coccidia but without apparent clinical signs. 
Coccidiasis is much more prevalent than coccidiosis and is thought to result in poor feed 
efficiency under intensive rearing conditions. [1] 
 
Anticoccidial drugs:  
  
Many drugs are available for prevention and treatment of coccidiosis in chickens, and in 
turkeys. Anticoccidials are usually given to poultry in the feed to prevent acute disease and 
the economic loss often associated with subacute infection. [2] They can be used also for 
prophylactic purpose because most of the damage occurs before signs become apparent, 
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and delayed treatment may not benefit the entire flock. Water medication is better than 
feed medication for therapeutic treatment. Antibiotics and increased levels of vitamins A 
and K are sometimes added to the diet to improve rate of recovery and prevent secondary 
infections. [2] 
 
Continuous use of anticoccidial drugs may result in selection for and survival of drug-
resistant strains of coccidia. While there is little cross-resistance to anticoccidials with 
different modes of action, there is widespread resistance to most drugs. [3] 
 
There are two distinct classes of anticoccidials: [4] 
1.) Coccidiostats that inhibit growth of intracellular coccidia, giving rise to latent 
infection after drug withdrawal. 
2.)  Coccidiocides, which destroy coccidia during their development. Some 
anticoccidial drugs may be initially coccidiostatic but after long use become 
coccidiocidal. Most anticoccidials currently used in poultry production are 
coccidiocides. [4] 
 
Many pharmaceutical veterinary products are available in the market for the treatment and 
control of coccidiosis and some contains several active ingredients such as Amprocoxin-
silv (brand drug) and A.S.K powder (generic drug).  
A.S.K Powder is a veterinary drug which is currently manufactured by Pharmacare 
pharmaceutical company in Palestine (See Table 1.1). It is a generic drug which is similar 
in composition to Amprocoxin-silv® that manufactured by Silvavet company for veterinary 
medicines. 
A.S.K Powder is used in veterinary field for the following reasons: 
1) Prevention and treatment of coccidiosis in poultry, lambs, calves and pigs. 
2) Control of coccidiosis and acute fowl cholera in chickens and acute fowl cholera and 
coccidiosis in turkeys, when caused by pathogens susceptible to sulfaquinoxaline.  
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Table (1.1): Pharmaceutical and clinical information of A.S.K Powder: 
 
Product Name A.S.K 
Pharmaceutical Form Powder 
Groups Anticoccidia 
Packages 200g 
Composition Each 1g Contains: 
Amprolium HCl   200   mg 
Sulfaquinoxaline sodium   200   mg 
Vitamin K3   2   mg 
Indications "Amprolium is considered as a common compound which is 
used as anti-coccidia in layer and hens mothers during fosterage 
period. It has very low poisoning level, its activity increases 
when it is associated with Sulfaquinoxaline. It has good effect 
against Eimeria tenella, Eimeria necatrix, medium effect against 
Eimeria acervuline and weak effect against Eimeria aximia and 
Eimeria brunetti. It is used to treat coccidia especially when 
coccidia accompanied with E. coli, salmonella and 
staphylococcus." [5] 
Usage and Dosage It is used with drinking water. 
100g for each 200 liters of drinking water daily. [5] 
The treatment continues for 3 days then stopped for 3 days then 
resumed for 3 other days. [5] 
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Brief description of the drugs combination used in the study: 
 
1.) Amprolium hydrochloride is 1-[(4-Amino-2-propyl-5-pyrimidinyl) methyl]-2-
picolinium chloride monohydrochloride. (C14H19ClN4 ·HCl; M.Wt. = 315.24).  
 
N
CH3
N
N
NH2
CH3
+
.HCl
Cl -
 
It is white to light yellow powder, freely soluble in water, in methanol, in alcohol, and in 
dimethylformamide; sparingly soluble in dehydrated alcohol; practically insoluble in 
isopropyl alcohol, in butyl alcohol, and in acetone. [6] 
Mechanism of action:  
It is structurally related to vitamin thiamine and the antiparasitic activity of the drug is 
thought to be related to competitive inhibition of active thiamine transport into the parasite. 
[7]
 
 
Indications and clinical uses: 
Amprolium is used to control and treat coccidiosis in calves, sheep, goats, puppies, and 
birds. It is administered orally, often mixed with food. [8] 
Since amprolium has poor activity against some Eimeria spp , its spectrum has been extended 
by using it in mixtures with the folic acid antagonists, ethopabate and sulfaquinoxaline. [9] 
Amprolium is thought to act primarily upon the first generation schizont in the cells of the 
intestinal wall, preventing differentiation of the metrozoites. It may suppress the sexual stages 
and sporulation of the oocysts. [10] 
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Amprolium is a thiamine analogue. Concurrent administration of thiamine can antagonize 
anticoccidial activity of Amprolium. [11] 
 
2.) Sulfaquinoxaline sodium is N'1-Quinoxalin-2-ylsulphanilamide sodium salt 
(C14H11N4NaO2S; M.Wt. = 322.32)  
NH2
S
O
N
N
N
O
-
Na
+
 
It is white to yellow powder, solubility in H2O: 50 mg/ml clear to slightly hazy, yellow to 
dark yellow solution. [12] 
Mechanism of action:  
Sulfaquinoxaline is a derivative of sulfanilamide (structurally similar to para-aminobenzoic 
acid) and it competes with para-aminobenzoic acid (PABA) for enzyme that synthesizes 
dihydrofolic acid in bacteria. [13] 
 
Indications and clinical uses: 
Sulfaquinoxaline is an oral baceriostatic antibiotic and coccidiostat. It is used for the 
prevention and treatment of intestinal coccidiosis and, in rabbits, hepatic coccidiosis due to 
Eimeria Stiedae. [14] 
Chronic treatment with sulfquinoxaline leads to vitamin deficiency, especially vitamin K. [15] 
"For the use in poultry, Sulfaquinoxaline has been administered to control coccidiosis. Mathis 
and McDougald (1984) described the therapeutic effectiveness of sulfaquinoxaline and 
Sulfaquinoxaline-pyrimethamine against several coccidia species of Eimeria. It was determined 
from that study that both Sulfaquinoxaline and Sulfaquinoxaline-pyrimethamine were highly 
effective against E. acervulina but less effective against E. tenella. In addition, the potentiated 
mixture was determined to be more effective against E.tenella than Sulfaquinoxaline alone, 
although neither mixture was found to be particularly effective against any cecal coccidia.  
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Amprolium was found to be efficacious against cecal-dwelling forms of coccidia, hence 
amprolium has been combined with Sulfaquinoxaline or Sulfaquinoxaline-pyrimethamine to 
enhance the spectrum of activity. Ineffectiveness of Sulfaquinoxaline-pyrimethamine against 
E.tenella has also been documented in another study (chapman 1989), underlining the 
importance of correct cocciadia species identification before instituting anticoccidial therapy 
with sulfaquinoxaline or any other sulfonamide". [16] 
 
3.) Vitamin K3 sodium bisulfite (menadione sodium bisulfite) is 4-Naphthalenedione, 2-
methyl-.  2-Methyl-1, 4-naphthoquinone (C11H9NaO5S; M.Wt. = 276.24; CAS Registry 
Number: 130-37-0) 
S
O
O
O
O
O
-
Na
+
 
It is white to off-white powder; soluble in water (50mg/ml give clear colorless to light yellow 
solution). [17] 
 
Menadione sodium bisulfate (Anti-blood) is a synthetic vitamin K compound used for the 
treatment of prolonged bleeding due to Vitamin K deficiency states. [18] 
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1.2 Modes of High Performance Liquid Chromatography (HPLC) 
 
In the modern pharmaceutical industry, HPLC is still the major and integral analytical tool 
applied in all stages of drug discovery, development, and production. HPLC is one of the 
most important techniques in pharmaceuticals analysis, because of its speed, efficiency of 
separation, versatility, sensitivity, and its convenience for qualitative & quantitative 
analysis. 
 
Chromatographic separations are based on a forced transport of the liquid mobile phase 
carrying the analyte mixture through the stationary phase. The differences in the 
interactions of the analytes with the surface of this stationary phase or the differences in 
the sizes and shape of the analytes resulting in different retention times for mixture 
components. [19] 
 
There are different modes of liquid chromatographic methods. Our focus in this section is 
on partition chromatography in which there is a competition between two immiscible 
solvents; stationary phase and mobile phase. The main types of HPLC techniques are 
partition, ion-exchange (IEX), and size-exclusion (SEC). There are three basic types of 
molecular forces that can be involved in these as shown below: [20] 
 
1. Polar forces are the dominant type of molecular interactions employed in NP HPLC. 
2. Dispersive forces are employed in RP HPLC  
3. Ionic forces are employed in IEX HPLC  
The fourth type of HPLC technique, SEC HPLC is based on the size and shape of analyte 
separated.  
 
1.2.1. Ion-Exchange chromatography (IEX): 
 
The separation in this method is based on the different affinities of the analyte ions for the 
oppositely charged ionic centers in the stationary phase or adsorbed counterions in the 
hydrophobic stationary phase. Depending on the charge of the exchange centers on the 
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surface of the stationary phase, the resin could be either anion-exchanger (positive ionic 
centers on the surface) or cation-exchanger (negative centers on the surface). [21] 
 
1.2.2. Partition Chromatography or Liquid/liquid Chromatography (LLC): 
 
The stationary phase is an immobilized liquid upon an inert and porous material. [22] This 
technique can be subdivided into liquid-liquid and bonded phase chromatography. The 
main difference is the method by which the stationary phase in helded on the support 
particles of the packing. In the former, the stationary phase is retained on the surface of the 
support by physical adsorption while in the later, it is bonded chemically. Bonded phase is 
more popular nowadays due to the more stability of the stationary phase. [23] 
 
The separation in this technique depends upon the distribution of sample components 
between two immiscible phases, according to their relative solubilities. The stationary 
phase being held in a column in the form of thin form on the support, and the mobile phase 
being forced through the column carrying the sample components along. To avoid mixing 
of the two phases the two partitioning liquids must differ greatly in polarity. 
 
The degree of interaction of analytes with the mobile phase and the stationary phase 
whether normal or reversed, affects the retention time of the analytes. In principle, the 
polarity of the stationary phase can lead to the following situations: [24] 
 
Normal phase HPLC:  in this mode, the stationary phase is a relatively polar and the 
mobile phase is a nonpolar. [24] Retention occurs through polar interactions, such as 
hydrogen bonding and dipole interactions, between the solute and the stationary phase. [25] 
 
Reversed-phase HPLC:  in this mode, the stationary phase is a relatively nonpolar and the 
mobile phase is a polar, the polar components favor the mobile phase and elute faster. [24] 
 
RP chromatography is the preferred HPLC mode in the pharmaceutical industry due to its 
mobile-phase compatibility with the typical polar drug substance, the higher efficiencies 
associated with this mode, shorter re-equilibration times, and the ability to run gradient 
methods covering a large range in polarity. [26] 
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Paired-ion chromatography (PIC) or Ion-pair chromatography is a technique related to RP-
HPLC that are established for the separation of highly polar compounds such as amino 
acids and organic acids that do not adhere at all to the stationary phase if it is nonpolar . 
Thus this polar character must be reduced to increase retention. To modify the ionic charge 
a strongly ionic reagent, called a ion pairing reagent, is added to the mobile phase. This is 
usually a compound with a carbon chain (weakly polar) possessing a functionality whose 
charge is opposite to the analyte to be separated (e.g. heptane sulfonic acid if the ionic 
solute is a base). This forms a ‘neutralized’ ion pair, a less polar species, fairly stable and 
lipophilic, which will initially stick to non polar stationary phase but can still be eluted, 
apparently by a type of ion-exchange mechanism. [27] So to make the ionic compound have 
sufficient lipophilic character to be retained by the column, a counter ion (pairing ion) is 
added to the eluent. The sample ion, x-n, plus the counter ion, Q+n, combine to form an ion 
pair (x-n Q+n  ) which has sufficient affinity for the reverse phase column to be retained by 
it . [28] 
 
The use of PIC is not always preferable since a thorough washing of the column is needed 
after separation. The reproducibility of the column however is not stable.  
 
Another practical alternative is to use relatively new column technology, the HILIC 
chromatography. 
 
1.2.3. Hydrophilic Interaction Liquid Chromatography (HILIC): 
 
Another option to conventional NP chromatography is hydrophilic interaction 
chromatography (HILIC). This technique utilizes a polar stationary phase with 
aqueous/organic mobile phase but with very high percentages of organic modifier. A 
simple acetonitrile/aqueous buffer mobile phase is commonly utilized in conjunction with 
a silica or amino stationary phase. The most common used buffer salt is the ammonium 
acetate because it possesses good solubility at high organic content. 
 
An adsorbed water layer on the silica substrate is formed under these chromatographic 
conditions. Polar solutes partition from the highly organic bulk mobile phase into the 
adsorbed water layer where they can undergo polar interactions. In addition, positively 
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charged solutes, such as amines, can undergo ionic interactions with charged silanol 
groups. As a consequence, retention of solutes increases with their increasing polarity. This 
mode is particularly useful for the separation of very polar solutes and/or raw materials that 
show minimal or no retention under RP conditions and are very strongly retained under NP 
conditions. [29] 
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1.3 HPLC Analytical Method Validation 
  
GLP requires that any chromatographic method, which is used to assess compliance of the 
pharmaceutical product with established specification, must meet proper standard of 
accuracy and reliability. A validated method can give consistent and reliable results. The 
validation is mainly concerned with source of errors and their estimation in the 
experimental results. If the estimated errors are within the acceptance limit, then the 
method is qualified for its intended use.  
 
When analytical methods need to be validated or revalidated? 
 
1.) Before introduction of  a new method into routine use. 
2.) Whenever the conditions are changed to which the method has been validated (e.g., an 
instrument with different characteristics or sample with a different matrix), and 
3.) Whenever the method is changed and the change is outside the original scope of the 
method. 
 
Analytical validation should be performed as soon as possible after development of the 
method, and must be completed before the results are used for registration or product 
release. 
Validation should cover all stages through sample selection and preparation, analyte 
recovery, suitability of equipment, and the assessment, interpretation and reporting of 
results. 
 
Validation of methods for the quantitative analysis of drugs involves determining as 
minimum, their specificity, linearity, working range, accuracy and precision under the 
conditions and with the typical sample matrices that will be met in practice. 
 
Validation of an analytical procedure is the process by which it is established, by laboratory 
studies, that the performance characteristics of the procedure meet the requirements for the 
intended analytical applications. [30] 
 
 
12 
 
 
Types of Analytical Procedures to be validated: [31] 
 
The discussion of the validation of analytical procedures is directed to the four most 
common types of analytical procedures: 
 
• Identification tests. 
• Quantitative tests for impurities' content. 
• Limit tests for the control of impurities. 
• Quantitative tests of the active moiety in samples of drug substance or drug product  
 
A brief description of the types of tests considered above is provided below: 
 
• Identification tests are intended to ensure the identity of an analyte in a sample. This is 
normally achieved by comparison of a property of the sample (e.g., spectrum, 
chromatographic behavior, chemical reactivity, etc) to that of a reference standard. 
• Testing for impurities can be either a quantitative test or a limit test for the impurity in a 
sample.  
• Assay procedures are intended to measure the analyte present in a given sample. In the 
context of this document, the assay represents a quantitative measurement of the major 
component(s) in the drug substance.  
 
Typical validation characteristics which should be performed are listed in table (1.2). 
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Table (1.2): Typical validation characteristics which should be performed according 
to ICH/USP33 guidelines [32] 
 
Analytical 
Performance 
Characteristics 
Assay Identification Impurity 
quantitative 
Impurity 
qualitative 
Specificity Yes       Yes Yes Yes 
Linearity        Yes      No Yes No 
Range Yes      No Yes No 
Accuracy        Yes     No Yes No 
Precision 
-Repeatability 
-Intermediate precision 
 
       Yes 
       Yes 
     No 
     No 
 
Yes 
Yes 
 
No 
No 
Detection Limit        No      No Yes /No Yes 
Quantitation Limit          No     No Yes No 
Robustness        Yes    Yes Yes Yes 
 
“Analytical Procedure: The analytical procedure refers to the way of performing the analysis. 
It should describe in detail the steps necessary to perform each analytical test. This may include 
but is not limited to: the sample, the reference standard and the reagents preparations, use of 
the apparatus, generation of the calibration curve, use of the formulae for the calculation,... etc. 
" 
[33]
 
 
"Specificity: it is the ability to assess unequivocally the analyte in the presence of 
components which may be expected to be present. Typically these might include 
impurities, degradants, matrix, etc". [33] Lack of specificity of an individual analytical 
procedure may be compensated by other supporting analytical procedure(s). [33] 
 
"Linearity: The linearity of an analytical procedure is its ability (within a given range) to 
obtain test results which are directly proportional to the concentration (amount) of analyte 
in the sample." [33] 
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"Range: The range of an analytical procedure is the interval between the upper and lower 
concentration (amounts) of analyte in the sample (including these concentrations) for which it 
has been demonstrated that the analytical procedure has a suitable level of precision, accuracy 
and linearity." [33] 
 
"Accuracy: The accuracy of an analytical procedure expresses the closeness of agreement 
between the value which is accepted either as a conventional true value or an accepted 
reference value and the value found." [33] 
 
"Precision: The precision of an analytical procedure expresses the closeness of agreement 
(degree of scatter) between a series of measurements obtained from multiple sampling of the 
same homogeneous sample under the prescribed conditions. Precision may be considered at 
three levels: repeatability, intermediate precision and reproducibility." [33] 
 
"Repeatability: The precision under the same operating conditions over a short interval of 
time. Repeatability is also termed intra-assay precision." [33] 
 
"Intermediate precision: The precision within-laboratories variations: different days, 
different analysts, different equipment, etc." [33] 
 
"Detection limit: The detection limit of an individual analytical procedure is the lowest 
amount of analyte in a sample which can be detected but not necessarily quantitated as an 
exact value." [33]  
The detection limit (DL) can be determined based on the standard deviation of the response 
and the slope as expressed in the below formula: 
 
S.D:  The standard deviation of the response 
Slope: The slope of the calibration curve 
"Quantitation limit: The quantitation limit of an individual analytical procedure is the lowest amount of 
analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The 
quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices, and is 
used particularly for the determination of impurities and/or degradation products."[33]  
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The quantitation limit (QL) can be determined based on the standard deviation of the 
response and the slope as expressed in the below formula: 
 
S.D:  The standard deviation of the response 
Slope: The slope of the calibration curve 
 
"Robustness: Measure of an analytical procedure’s capacity to remain unaffected by small 
but deliberate variations in method parameters and provides an indication of its reliability 
during normal usage." [33] 
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1.4 Research Problem  
Pharmacare pharmaceutical company has developed a new generic veterinary product under 
the name of A.S.K Powder.  Up to now, this product can not be registered at the Ministry of 
Health in Palestine since there is no quality control method in the official pharmacopoeias or 
any other published validated method that enable us to analyze the drug combination 
simultaneously and perform stability studies including accelerated and long term stability 
studies which are the major requirements for registration of any pharmaceutical drug in 
Palestine or other countries. 
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1.5 The Objectives of this Research Project  
 
General objective: 
To develop an authentic validated quality control HPLC method to simultaneously analyze 
amprolium hydrochloride, sulfaquinoxaline sodium and vitamin K3 (menadione sodium 
bisulfite) in A.S.K Powder and perform stability studies that enable us to register the drug at 
the Ministry of Health in Palestine. 
Specific objectives: 
1.) Since there is no HPLC assay that applies to analyze the pharmaceutical combination of 
amprolium hydrochloride, sulfaquinoxaline sodium and vitamin K3 salt ingredients together 
this triggered us to develop a specific, fast and accurate HPLC method that allows the 
simultaneous separation within a reasonable retention time. 
 
2.) To validate the new developed method according to ICH and USP guidelines and 
specifications. The validated method will serve as authentic quality control method to analyze 
A.S.K Powder and perform the stability of the drug and thus register the drug in Palestine or 
in any other country in the future. 
 
3.) To publish this validated method in the British pharmacopoeia (BP) or United States 
pharmacopoeia (USP) as an official method for analysis of the three active components 
simultaneously.  
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1.6 Research Hypothesis  
Hydrophilic interaction liquid chromatography (HILIC) is a  relatively new technique that 
is designed for separation of very polar and hydrophilic compounds that may elutes with 
the void peak in the reversed phase system and solutes that have little or no retention on 
RPLC columns generally experience strong retention on HILIC columns. [34] 
 
The HILIC technique thus bears similarities with traditional NPLC, but with the important 
difference that HILIC employs semi-aqueous mobile phases. Consequently, with respect to 
analyte solubility in the eluent and matrix compatibility, HILIC is superior, as the mobile 
phase compositions used are comparable to RPLC separations. Typical eluents for HILIC 
consist of 40-97% acetonitrile in water or a volatile buffer. [34] 
Besides, HILIC is a very mass spectrometry (MS) friendly technique, and by changing 
from RPLC to HILIC a 10-1000 fold increase in sensitivity is often observed for 
hydrophilic analytes. Ion-pair reagents are also completely avoided, which is advantageous 
for preparative chromatography.[34] 
 
ZIC-HILIC columns contain a stationary phase that is hydrophilic and quite often also 
charged (Figure 1.1). Hydrophilic compounds are generally more strongly retained on the 
column by interacting with the stationary phase thus achieving separation. [35] 
 
 
 
Figure (1.1): The functional group of the ZIC®-HILIC [34] 
 
Under HILIC conditions, a water-enriched liquid layer will be established within the 
stationary phase. The separation is achieved by partitioning of solutes from the eluent into 
this hydrophilic environment (see Figure 1.2). Hence, both hydrogen bonding and dipole-
dipole interactions are factors governing retention. The retention will also be influenced by 
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electrostatic (ionic) interactions, as illustrated in Figure 1.2 for a zwitterionic stationary 
phase. [35] 
 
 
 
Figure (1.2): The retention processes in HILIC illustrated by hydrophilic partitioning, and 
electrostatic interactions with either positive or negative charges.[35] 
 
The permanently charged, yet overall neutral, highly polar zwitterionic ZIC®-HILIC 
material provides a unique environment, not only particularly capable of solvating polar 
and charged compounds, but also offering the possibility of weak electrostatic interaction 
with analytes carrying either positive or negative charges. The retention thus generally 
increases with hydrophilicity and with charge of the analyte, and the selectivity can be 
tuned while maintaining a low ionic strength. These properties make the ZIC®-HILIC 
material excellent for separations of a wide range of polar and hydrophilic compounds. 
 
The silica-based ZIC®-HILIC stationary phase carries a covalently bonded, permanently 
zwitterionic, functional group of the sulfobetaine type, see Figure 1.1.[36] 
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Chapter Two 
______________________________________________________________ 
Literature Review 
______________________________________________________________ 
 
The assays of combinations of active ingredients should be specific, and sensitive enough 
to analyze the active ingredients in pharmaceutical formulations without interferences. The 
method should also be fast, with a minimum sample manipulation, and of stability-
indicating capability. 
 
The three drugs that are used as a mixture in this veterinary combination need a fast HPLC 
method to separate and quantitate them simultaneously.  An extensive literatures survey 
using ScienceFinder (the largest and most comprehensive database) and the official 
pharmacopoeias did not reveal any method for the simultaneous separation, and assay 
determination of these components mixture in the drug.  
  
However, there are different non-chromatographic and chromatographic particularly RP- 
HPLC and ion-pair RP-HPLC methods of analysis that have been applied to assay these 
compounds individually or when present in combinations with other ingredients:  
The official BP2007 assay method for the quantitative determination of amprolium 
hydrochloride has been based on non-aqueous titration which is accurate, simple and rapid 
but it applies only to amprolium hydrochloride when present as active pharmaceutical 
ingredient and is not of stability-indicating nature. [37] 
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The official USP33/NF28 assay method for quantitative determination of amprolium 
hydrochloride has been based on HPLC, which is accurate, specific and simple but it applies 
only to amprolium hydrochloride present as active pharmaceutical ingredient. This method is 
based on reversed phase, ion-pair HPLC technique using sodium 1-heptanesulfonate , water, 
glacial acetic acid, triethylamine, methanol (MeOH), and ACN as a mobile phase and a 4.6-
mm × 25-cm column containing trimethylsilane chemically bonded to porous silica particles, 
3 to 10 µm in diameter. [38] 
The official USP33/NF28 assay method for quantitative determination of amprolium 
hydrochloride has been based on HPLC, which is accurate, simple and specific but it 
applies only when the amprolium hydrochloride is the only active ingredient in 
pharmaceutical formulations. Again, this method is based on reversed phase, ion-pair 
HPLC technique using sodium 1-hexanesulfonate, water, MeOH, and ACN as mobile 
phase and a 3.9-mm × 30-cm column that contains phenyl groups chemically bonded to 
porous silica particles, 1.5 to 10 µm in diameter. [39] 
  
The official BP2007 assay method for quantitative determination of sulfaquinoxaline has 
been based on titration which is accurate, fast and simple but it applies only to 
sulfaquinoxaline when present as active pharmaceutical ingredient and is not of stability 
indicating nature. [40] 
 
The official USP33/NF28 assay method for quantitative determination of sulfaquinoxaline 
has been based on HPLC, which is accurate, simple and fast but it applies only when the 
sulfaquinoxaline is present as active pharmaceutical ingredient or is the only active 
ingredient in the pharmaceutical preparations. This method is based on reversed phase 
HPLC technique using monobasic ammonium phosphate, water, ACN, glacial acetic acid, 
tetrahydrofuran, and ammonium hydroxide as mobile phase and a 4-mm × 25-cm column 
that contains octadecyl silane chemically bonded to porous silica particles, 1.5 to 10 µm in 
diameter. [41] 
 
The official USP33/NF28 assay method for quantitative determination of menadione has 
been based on oxidation-reduction titration, which is accurate, and fast but it applies only 
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to menadione present as an active pharmaceutical ingredient and needs chemical 
manipulation. The method is not of   stability-indicating nature. [42] 
 
The official USP33/NF28 assay method for quantitative determination of menadione has 
been based on ultraviolet/visible spectrophotometric method which leads to extensive 
interferences when used in the drug combination of A.S.K Powder. The method applies 
only when the menadione is the only active ingredient in the dosage forms and is not of 
stability-indicating nature. The method is time consuming and requires some chemical 
manipulation. [43] 
 
The official BP2007 assay method for quantitative determination of menadione has been 
based on oxidation-reduction titration method, which is accurate, simple and fast but it 
applies only when the menadione is present as active pharmaceutical ingredient and need 
some chemical manipulation. [44] 
 
Cheng, Huang, Chang, Yao, and Hwang (2008) have developed an HPLC method for the 
selective separation of sulfapyridine (SPD) from sulfaquinoxaline (SQX). The method was 
carried out with molecularly imprinted polymer (MIP) as the stationary phase and 
34mmol/ml sodium dihydrogen phosphate buffer solution /ACN (3/2, v/v) as mobile phase 
under 272 nm UV detection. [45] 
 
Lakkanatinaporn and Matayatsuk   (2004) have developed a simple HPLC method for the 
separation and determination of sodium trimethoprim phenylpropanol disulphonate and 
sodium sulfaquinoxaline in veterinary preparations. Both drugs were separated well on a 
Kromasil C18 column (5 µm, 150 × 4.6 mm) using a mixture of ACN and 0.5% 
triethylamine in 1% acetic acid, pH 3 (18:82, v/v) as the mobile phase at the flow rate of 
1.5 ml/min. The presence of both substances was monitored by UV absorption detection at 
271 nm. [46] The method is accurate, specific, precise and fast.  
 
Cruz, Soares, Marquesb and de Aquino-Netoa (2002) have developed an HPLC- 
electrospray ionization - tandem mass spectrometry (LC-ESI-MS/MS) to simultaneous 
determination of ten sulfonamide (SAs) residues (sulfacetamide, sulfathiazole, 
sulfamerazine, sulfamethazine, sulfamethoxypyridazine, sulfamethizole, 
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sulfachloropyridazine, sulfamethoxazole, sulfadimethoxine and sulfaquinoxaline) in eggs. 
Samples were extracted with acetonitrile and the supernatants were cleaned up by solid 
phase extraction. After solvent evaporation and reconstitution, aliquots of the final extracts 
were injected into a LC-ESI-MS/MS.  
The mobile phase used was ultrapure water (A) and ACN (B), both with 0.1% of formic 
acid, with a constant flow of 1 ml min-1. Gradient elution started with 100% of A, then 
decreased to 50% in 10 min, returning to 100% in 1 min and remaining in 100% for 1 min. 
The column used was a reversed phase column C18 150 × 4.6 mm, 5 mm, X-Terra, Waters 
(Milford, USA). [47] This method requires extensive extraction which leads in many cases 
to non-reproducibility and requires trained technicians and it is very costly.  
 
Kishida (2001) has developed a simple HPLC method for routine monitoring of seven 
residual sulfonamides (sulfadiazine (SDZ), sulfamerazine (SMR), sulfadimidine (SDD), 
sulfamonomethoxine (SMM), sulfamethoxazole (SMX), sulfadimethoxine (SDM), and 
sulfaquinoxaline (SQ)) in milk. The HPLC method was done on RP-4 column and 25 %( 
v/v) aqueous ethanol solution as mobile phase. Eluate was monitored using a photodiode 
array detector set at 269 nm. The method has been applied only after the sample was 
cleaned up by using an Ultrafree®-MC/PL centrifugal ultrafiltration unit. The average 
recoveries of each active were more than 82% and the HPLC analysis time is below 22 
minutes. [48] 
This method requires extensive extraction which leads in many cases to non-
reproducibility and requires trained technicians.  
 
Kozhanova, Fedorova, and Baram (2000) have developed a simple HPLC method for the 
separation and determination of Water- and Fat-Soluble Vitamins in Multivitamin 
Preparations. The method is capable of determination of vitamins B1 and B2, nicotinic acid, 
nicotinamide, pantothenic acid, folic acid, vitamins B6, B12, K3, H, D2, and D3, and vitamin 
A and E acetates in multivitamin preparations using two chromatographic procedures. The 
vitamins were separated on column with the Nucleosil 100-5 C18 reversed-phase sorbent 
and use gradient elution mode for water soluble vitamins and the isocratic mode for fat-
soluble vitamins .The presence of these vitamins were monitored by UV absorption 
detection at different wavelength. [49] The method is accurate, fast but need some sample 
manipulation and trained technicians.  
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Ya-Min Kao , Mei-Hua Chang, Chieu-Chen Cheng And Shin-Shou Chou (2000) have 
developed an HPLC method for the residual determination of 13 veterinary drugs, 
including clopidol, sulfadiazine, sulfathiazole, carbadox, sulfamerazine, ormethoprim, 
sulfamethazine, furazolidone, sulfamonomethoxine, sulfamethoxazole, ethopabate, 
sulfaquinoxaline, and sulfadimethoxine in chicken and swine muscles. Test samples were 
extracted with acetonitrile and filtered. The filtrate was partitioned with ACN-saturated n-
hexane for removing the interference. After evaporation to dryness, the residue was passed 
through a Sep-Pak C18 cartridge for sample cleanup prior to HPLC analysis. The HPLC 
method was equipped with a photodiode array detector using a C18 (25 cm× 4.6 mm i.d., 5 
µm) analytical column and a gradient elution of ACN and 0.05M sodium dihydrogen 
phosphate. [50] 
However, the extraction and purification of these methods involves numerous and varying 
analytical steps which are labor intensive and time consuming and needs trained 
technicians.  
 
Filimonov, Zamuraev, Balyatinskaya, and Kolosova (1999) have developed HPLC method 
for the determination of the synthetic fat-soluble vitamins including vitamins E acetate, K3, 
D2 in Hexavet, Undevit, and Hendevit multivitamin pharmaceutical preparations. This 
method is based on normal phase HPLC technique using hydroxylated silica gel column (100 
×5.4 mm) and n-hexane with polar solvents additives (aliphatic alcohols, dichloromethane, or 
1,2-dichloroethane)  as a mobile phase and monitored at UV absorption wavelength of 254 
nm.  The method is accurate, simple and fast. [51] 
Boulaire, Bauduret, and Andre ( 1997) have developed an HPLC method with Matrix solid 
phase dispersion extraction technique for the isolation and determination of 14 veterinary 
drug residues (sulfathiazole, STH; sulfamerazine, SMR; sulfachloropyridazine, SCP; 
sulfamethazine, SMT; sulfamethoxypyridazine, SMO; sulfamethoxazole, SMA; 
sulfaquinoxaline, SQX; sulfadimethoxine, SDX; thiabendazole; mebendazole; nicarbazin; 
chloramphenicol ; furazolidone and Virginiamycin ) in meat . Matrix solid phase dispersion 
(MSPD) was chosen as the extraction technique for this screening method. After extraction 
reversed-phase C18 column was used for the high performance liquid chromatography 
(HPLC) to separate the analytes with gradients of NH4AC buffer-ACN-MeOH as mobile 
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phase. Photodiode array and fluorimetric detectors were used for this analysis. However, the 
extraction and purification of these methods involves numerous and varying analytical steps 
which are labor intensive and time consuming and needs trained technicians. [52] 
Tan, Ramachandran 2, and Cacini (1996) have developed HPLC method for the assay of 
mixtures of amprolium and ethopabate in chicken feed utilizing reversed-phase high-
performance liquid chromatography (HPLC). HPLC was done on a C-8 column with MeOH-
water 40:60, containing octanesulfonic acid, triethylamine and acetic acid, as mobile phase. 
Eluate was monitored at 274 nm. [53]  
The method has been applied only after the sample is extracted through solid phase extraction 
by passing methanol followed by distilled water and then treatment with HCl, ammonium 
hydroxide solution and finally centrifugation. This method is time consuming and there is 
possibility of active ingredients loss during the extraction, washing and centrifugation steps.  
Ralph Hindle has developed a simple HPLC method for the analysis of sulfonamide 
antibiotics in pork muscle.  The HPLC method was done on Zorbax  XDB-C8,150mm ×4.6 
mm,5µml  with gradients of 0.1%formic acid in water (solvent A) and 0.1%formic acid in 
acetonitrile (solvent B)  as mobile phase. The method is based on HPLC Mass spectroscopy 
using chemical ionization. [54] 
The method has been applied only after the samples were extracted with acidified methanol 
and centrifuged. This method requires extensive extraction which leads in many cases to non-
reproducibility and requires trained technicians.  
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Chapter Three 
______________________________________________________________ 
Experimental Part 
_________________________________________________________________________ 
 
3.1 Chemicals and Reagents 
 
Ammonium acetate extra pure (Merck, Germany) 
Acetic acid (Glacial) 100% (Merck, Germany) 
Methanol HPLC grade (Merck, Germany)  
Acetonitrile HPLC grade (Merck, Germany)  
Hydrochloric acid fuming 37% (Merck, Germany) 
Sodium hydroxide pellets GR for synthesis (Merck, Germany)  
Hydrogen peroxide 30% for analysis (Merck, Germany)  
Amprolium hydrochloride reference standard 99.4% (Lot no: SZBA068X) were purchased 
from Sigma-Aldrich (Germany) 
Sulfaquinoxaline sodium reference standard   99.9% (Lot no: BCBB7740V) were 
purchased from Sigma-Aldrich (Germany) 
Menadione sodium bisulfite reference standard   98% (Lot no: 048K1372) were purchased 
from Sigma-Aldrich (Germany) 
Purified water (0.45 µm, Conductivity: Maximum 1.3µs/cm, TOC: Maximum 500 ppb).  
A.S.K Powder samples were supplied by Pharmacare pharmaceutical company 
All active ingredients and excipients usually used in manufacturing the pharmaceutical 
combination, were kindly supplied by Pharmacare pharmaceutical company 
27 
 
 
Hexane-1-sulfonic acid sodium salt for ion pair chromatography LiChropur (Merck, 
Germany) 
Decane-1-sulfonic acid sodium salt (Merck, Germany) 
Triethylamine (Merck, Germany) 
Ammonia solution 25% for analysis, (Merck, Germany) 
 
3.2 Apparatus and Laboratory equipment 
 
Ultraviolet/visible spectrometer (PG Instruments, United Kingdom) 
Elite Lachrom high performance liquid chromatograph equipped with UV-Detector and 
supported with autosampler and column oven and Elite Lachrom data system of Agilent 
(Merck Hitachi , England) 
Laboratory glassware (volumetric flasks, measuring cylinders, beakers, volumetric 
pipettes, and graduated pipettes) 
Disposable Syringe 5ml, (Shandong Zibo shanchuan medical instruments CO., Ltd., 
China) 
Syringe filters (Nylon 66) pore size 0.45µm, diameter 25mm (Axiva Sichem Biotech, 
India). 
Magnetic stirrer model F-13 (Fried Electric, Haifa) 
Mettler Toledo pH meter MP230 (Sigma-Aldrich, Germany) 
Sonicator (Branson Ultrasonics Corporation, USA) 
Vacuum pump & filtration assembly (NDS Technologies.Inc, Vineland) 
Weighing balance (Ohaus, USA) 
 
3.3 Analytical procedure 
 
3.3.1. Chromatographic conditions: 
 
The column utilized was a ZIC®-HILIC column (25.0 cm long ×4.6 mm i.d.) with particle 
size of 5 µm (Merck, Germany) protected with a ZIC®-HILIC guard column (20mm× 
2.1mm, 5µm). The guard column was used to prolong the life time of the column and to 
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The 0.2 M Ammonium acetate was prepared by dissolving 3.08 g of NH4AC in purified 
water and diluted to 200 ml with the same solvent. 
 
 
The optimum mobile phase finally selected for the assay was prepared by mixing 0.2 M 
NH4AC and ACN (15:85; v/v), shaken well and left tell the temperature of the mobile 
phase reached to the room temperature. Then pH was adjusted to 5.7 by glacial acetic acid. 
The mobile phase was filtered using 0.45 µm microporous filters and was degassed by 
sonication prior to use. The standard and sample solutions were filtered using 0.45 µm 
membrane filters to prolong pump life and to avoid column blockage by any particulate 
matter.  
 
The wavelength of 263 nm was chosen because it was found most appropriate for the three 
compounds simultaneously. The flow rate was 0.5 ml/minute as recommended by the 
column manufacturer whereby minimum height equivalent to theoretical plates and 
maximum number of theoretical plates are generated. 
 
The injection volume was 20 µl and the temperature of the autosampler was 15°C and that 
of the column was 25° C. Total run time was about 18 minutes.  
 
3.3.2. Preparation of stock and standard solutions: 
 
Stock solution for menadione sodium bisulfite was prepared by dissolving Menadione 
sodium bisulfite reference standard equivalent to 20 mg menadione (vitamin K3) in 80.0 ml 
of 90% ACN and diluting to 100.0 ml with the same solvent. 5 ml of this solution was 
diluted to 50 ml with 90% ACN. This brings about a concentration of 20.0µg/ml.  
 
Standard solution for amprolium HCl, sulfaquinoxaline sodium and vitamin K3 was 
prepared by dissolving  20.0 mg of amprolium hydrochloride reference standard, 20 mg 
sulfaquinoxaline sodium reference standard in 70.0 ml of 90% ACN, 10 ml of menadione 
sodium bisulfite stock solution was added , mixed well and the diluted to 100.0 ml with 
90% ACN. Then 5 ml of this solution was diluted to 50 ml with mobile phase. The solution 
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was filtered using 0.45 µm membrane filters. Final concentration was 20 µg/ml for 
amprolium hydrochloride, 20 µg/ml for sulfaquinoxaline sodium and 0.20µg/ml for 
vitamin K3.  This solution has been used within 24 hours if kept at 15 °C and protected 
from light.  
 
 
3.3.3. Preparation of sample solution: 
 
Sample solution was prepared by dissolving 100 mg of A.S.K Powder in 80 ml of 90% 
ACN and then diluted to 100 ml with the same solvent. Then 5 ml of this sample solution 
was diluted to 50 ml with mobile phase. The solution was filtered using 0.45 µm 
membrane filters. Final concentration was 20 µg/ml for amprolium hydrochloride, 20 
µg/ml for sulfaquinoxaline sodium and 0.20µg/ml for vitamin K3.  This solution has been 
used within 24 hours if kept at 15 °C and protected from light.  
 
3.3.4. Calculations: 
 
Since the validation results indicated that the peak areas were linearly proportional to 
concentrations over a range of 12 µg/ml to 26µg/ml for amprolium hydrochloride, 12 
µg/ml to 26µg/ml for sulfaquinoxaline sodium and 0.12 µg/ml to 0.26µg/ml for vitamin K3 
and also, as a consequence of linearity relationship, the amounts injected were always 
within the ranges of linearity found for these three compounds, the results were calculated 
using the following formulas: 
 
Where; 
Psa.: Average area of peak corresponding to amprolium hydrochloride in sample solution 
chromatograms. 
Pst.: Average area of peak corresponding to amprolium hydrochloride in standard solution 
chromatograms 
Cst.: Concentration of  amprolium HCl in the standard preparation (µg /ml)= 20µg /ml 
Csa.: Concentration of amprolium HCl in the sample preparation (µg/ml)= 20µg /ml 
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P: % assay of amprolium hydrochloride working standard (Anhydrous basis) 
W= Water content of working standard 
  
  
Where; 
 
Psa.: Average area of peak corresponding to sulfaquinoxaline sodium in sample solution 
chromatograms. 
Pst.: Average area of peak corresponding to sulfaquinoxaline sodium in standard solution 
chromatograms 
Cst.: Concentration of sulfaquinoxaline sodium in the standard preparation (µg /ml)= 20µg 
/ml 
Csa.: Concentration of sulfaquinoxaline sodium in the sample preparation (µg/ml)= 20µg 
/ml 
P: % assay of sulfaquinoxaline sodium working standard (Anhydrous basis) 
W= Water content of working standard  
 
 
       
Where; 
 
Psa.: Average area of peak corresponding to menadione  in sample solution 
chromatograms. 
Pst.: Average area of peak corresponding to menadione in standard solution 
chromatograms 
Cst.: Concentration of menadione sodium bisulfite in the standard preparation (µg /ml) = 
0.32µg /ml 
Csa.: Concentration of menadione in the sample preparation (µg/ml)= 0.20µg /ml 
P: % assay of menadione sodium bisulfite working standard (Anhydrous basis) 
W= Water content of working standard  
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172.18 and 276.24 are the molecular weights of menadione and menadione sodium 
bisulfite respectively. 
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Chapter Four 
______________________________________________________________ 
Results and Discussion  
______________________________________________________________ 
 
4.1 Development and Optimization of the HPLC Method  
 
Prior exploration of the best chromatographic conditions, the selection of an appropriate 
wavelength for all the compounds involved is a necessity. The overlaid ultraviolet 
absorption spectra for solutions of amprolium hydrochloride dissolved in mobile phase 
reveals two maxima namely 232 and 267nm, for sulfaquinoxaline sodium reveals two 
maxima at 249 and 263nm while for menadione sodium bisulfite reveals two maxima at 
231 and 260 nm . As shown from figure 4.1, we noticed that the three compounds almost 
shared a wavelength near to 263 nm, therefore, 263 nm was chosen as the most appropriate 
wavelength throughout the investigations.  
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Figure (4.1):  Overlaid UV-Spectra of the mixture of sulfaquinoxaline sodium (1), 
menadione sodium bisulfite (2) and amprolium hydrochloride (3), in the mobile phase 
(ACN: 0.2 M NH4AC buffer (85:15; v/v).  
 
First, we tried the reversed phase mode (RP- HPLC) by using different percentages of 
acetonitirle and 0.2 M ammonium acetate adjusted to pH 5.7 with glacial acetic acid as a 
mobile phase. The column was C18 (5µm, 250mm × 4.6mm). Upon testing all the mobile 
phases, no promising separation was achieved (i.e. all of them get eluted with the void 
peak) even when the concentration of ACN was minute (0.5%). It was expected that 
separation by RP-HPLC was impossible for such very polar compounds. 
Then, as an alternative, we tried ion pair chromatography in which the mobile phase was a 
mixture prepared by dissolving 2.0 g of sodium 1-hexanesulfonate in 500 ml of water; 12 
249 nm    
263 nm    
231 nm    
232 nm    260nm    
267nm    
34 
 
 
ml of glacial acetic acid, 2.0 ml of triethylamine, 450 ml of methanol, and 50 ml of 
acetonitrile. The column used was C18 (5µm, 250mm × 4.6mm). Poor separation profile 
was obtained (as shown in figure 4.2) where all the peaks were close to each other with no 
baseline separation and the retentions of all compounds were almost close to the void peak.   
 
 
Figure (4.2):  A typical chromatogram of mixture of sulfaquinoxaline sodium (4), 
sulfaquinoxaline related compound A  (3), vitamin K3 (1) and amprolium hydrochloride 
(2); Column, C18 (5µm, 250mm × 4.6mm ) ; Mobile phase consisting of 2.0 g of sodium 1-
hexanesulfonate in 500 ml of water; 12 ml of glacial acetic acid, 2.0 ml of triethylamine, 
450 ml of methanol and 50 ml of acetonitrile; flow rate 1.0 ml/min; λ =274nm; column 
temperature=25°C; Autosampler Temp.= 15°C.  
 
Another mobile phase was a mixture of 400 ml methanol, 600 ml water containing 1.0 g of 
sodium 1-decanesulfonate, 5 ml triethylamine, and 25 ml glacial acetic acid. The column 
used was C8 (5µm, 250mm × 4.6mm). Broad peak profiles were produced for all the 
compounds with high tailing factor (Figure 4.3). Moreover, the sensitivity was decreased 
to more than 40% for all peaks when compared to same mixture concentration analyzed by 
HILIC mode. 
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Figure (4.3):  A typical chromatogram of mixture of sulfaquinoxaline sodium (3), vitamin 
K3 (1) and amprolium hydrochloride (2); Column, C8 (5µm, 250mm × 4.6mm); Mobile 
phase consisting of a mixture of 400 ml methanol, 600 ml water containing 1.0 g of sodium 
1-decanesulfonate, 5 ml triethylamine, and 25 ml glacial acetic acid; flow rate 1.0 ml/min; 
λ =274nm; column temperature=25°C; Autosampler Temp. = 15°C.  
 
It is clear that the use of ion pair reagents decreased the assay sensitivity for all compounds 
particularly vitamin K3 since it is present at 0.2% level of the concentration of other 
compounds in the mixture.  Therefore, increasing the concentration of the ion pair reagent 
will greatly lower the sensitivity of vitamin K3 and increase the cost of analysis due to the 
expensive cost of ion-pair reagents. The unsatisfactory results obtained by RP and PIC, 
aided us in switching to HILIC technology. Utilizing this column spare the use of ion-pair 
reagents as well as naturally increasing the sensitivity of the eluted peaks and reducing the 
total analysis cost. 
 
The ZIC®-HILIC column (25.0 cm long ×4.6 mm i.d., dp=5 µm) was the next choice 
because of its suitability for the separation of a wide range of very polar and hydrophilic 
compounds. In addition, the separation of ionic and very polar compounds could be 
achieved by using this column with polar mobile phase that contains high portions of 
organic solvent.  
 
During the method development phase of this research work, different compositions of the 
mobile phase have been employed. These mobile phases differ in the pH, concentration of 
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NH4AC buffer, and organic solvent percentages. Moreover, different temperatures for the 
chromatographic column have been tried. 
 
Our first choice of a mobile phase was ACN/10 mM NH4AC buffer solution (80:20; v/v). 
The pH of the mobile phase was adjusted to pH of 5.0. Typically, as recommended by the 
column manufacturer, the mobile phase for HILIC consists of 40-97% ACN in water. To 
obtain reproducible results at least 3% of water should be maintained in the mobile phase. 
This amount of water is necessary to ensure sufficient hydration of the stationary phase 
particles. To the contrary of reversed phase, the ACN, one of the weaker solvents in 
HILIC, provides a much higher increase in retention compared to other solvents like 
methanol.  Suitable buffer for HILIC is ammonium salt of acetate due to its excellent 
solubility even in very high concentrations of organic solvent. It was found that no baseline 
separation was achieved for our active ingredients, i.e.; sulfaquinoxaline sodium and 
vitamin K3. Even amporlium hydrochloride was separated with total analysis time close to 
40 minutes, as shown in figure 4.4 and Table 4.1. 
 
4.1.1. The effect of buffer concentration: 
 
When the concentration of NH4AC was doubled (i.e., 20 mM) overlapped peaks with no 
baseline separation was achieved between sulfaquinoxaline sodium and vitamin K3 
compounds. The amprolium hydrochloride eluted far a way with a total analysis time of 
about 30 minutes, as shown in figure 4.4 and Table 4.1. 
 
When the ionic strength in the mobile phase was increased to 30, 40, and 50 mM NH4AC 
respectively, a baseline separation emerged with more reasonable resolution values (Rs). 
At this point, it was anticipated that the separation might be better with the increase of the 
concentration of ammonium acetate.  
 
Upon increasing NH4AC concentration to 75mM, clear separated peaks evolved. However, 
a new tiny peak between sulfaquinoxaline sodium and vitamin K3 emerged which is due to 
sulfaquinoxaline impurity (appears to be a degradation product) as seen in figure 4.5.  In 
order to improve the resolution, the concentration of NH4AC was further increased. 
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Therefore, solutions of 0.1 and 0.2 M NH4AC were tried. A much more pronounced 
baseline separation were obtained with Rs of 2.71 between sulfaquinoxaline sodium and its 
impurity and Rs  of 2.1 between sulfaquinoxaline sodium impurity and vitamin K3  at 
0.1M. The tailing factor of amproulim hydrochloride was 2.51. In the case of 0.2 M, the Rs 
of 2.3 between sulfaquinoxaline sodium and its impurity and Rs of 5.74 between 
sulfaquinoxaline sodium impurity and vitamin K3 was seen. 
 
The best separation and baseline resolution was achieved by using 0.2 M concentration 
with Rs >2.0 and total analysis time was less than 16 minutes (Figure 4.4, 4.6, table 4.1).  
 
The retention was slightly decreased by increasing ionic strength (salt concentration). This 
seems to imply that retention time was mainly based on hydrophilic interaction as the ionic 
strength increased, the positively charged ammonium ions in the mobile phase may 
weaken the hydrophilic interaction between protonated compounds and stationary phase 
which result in shortening the retention time 
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Figure (4.4):  Chromatograms obtained upon 20µl injection of a mixture of 
sulfaquinoxaline sodium (1) (20µg/ml), Vitamin K3 (2) (10µg/ml), and amprolium 
hydrochloride (3) (20µg/ml). Mobile phase consisting of ACN and NH4AC solution 
(80:20; v/v) adjusted to pH of 5.0; flow rate =0.5 ml/min; λ =263nm; the concentration of 
NH4AC is as shown in the figure. 
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Figure (4.5): Structure of Sulfaquinoxaline Related Compound A. [55] 
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Figure (4.6): Chromatograms obtained upon 20µl injection of a mixture of 
sulfaquinoxaline sodium (20µg/ml) (1), Vitamin K3 (2) (10µg/ml), and amprolium 
hydrochloride (3) (20µg/ml), sulfaquinoxaline impurity (4). Mobile phase consisting of 
ACN and NH4AC solution (80:20; v/v) adjusted to pH of 5.0; flow rate =0.5 ml/min; λ 
=263nm; the concentration of NH4AC is as shown in the figure. 
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Table (4.1): Effect of concentration of ammonium acetate on resolution (Rs) 
 
Concentration of 
NH4AC solution (M) 
*Rs 1.4 †Rs 2.4 ‡Rs1.2 ζRs 2.3 
0.01 0 0 0.89 25.51 
0.02 0 0 0.74 22.92 
0.03 0 0 1.47 21.7 
0.04 0 0 2.38 20.86 
0.05 0 0 2.87 20.27 
0.075 2.78 1.38 4.1 17.42 
0.1 2.71 2.1 4.8 16.16 
0.2 2.3 3.4 5.74 13.54 
 
*Rs 1.4: Represents the resolution value between sulfaquinoxaline sodium (1) and its 
impurity (4). 
†Rs 2.4 : Represents the resolution value between vitamin K3 (2) and sulfaquinoxaline 
sodium Impurity (4) 
‡Rs1.2 : Represents the resolution value between sulfaquinoxaline sodium (1) and vitamin 
K3 (2). 
ζ Rs 2.3: Represents the resolution value between vitamin K3 (2) and amprolium HCl (3) 
Resolution (Rs): The ratio of the distance between two peak maxima to the mean value of 
the peak width at the base line [56] 
 
 
 
TR2: Retention time of the second eluting peak 
TR1: Retention time of the first eluting peak 
W1: Peak width of the first peak at the base line 
W2: Peak width of the second peak at the base line 
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4.1.2. The effect of pH: 
 
A study of pH effects on the resolution of A.S.K compounds was deemed necessary to 
further optimize the separation conditions. The resolution values for sulfaquinoxaline 
sodium, sulfaquinoxaline sodium impurity, vitamin K3, and amprolium hydrochloride were 
significantly influenced by the variation of the pH of the mobile phase. 
 
We tried different pH values such as 3.5, 4.0, 4.5, 5.7, 6.0, 6.5 and 7.0. As shown in figure 
4.7 and table 4.2, variation of pH yielded maximum resolution for all compounds at pH 
5.7. In case of pH< 4.0, interference occurred between sulfaquinoxaline sodium and its 
impurity.  The Rs between vitamin K3 and amprolium hydrochloride was decreased to 1.47 
at pH of 4.5 even there is good Rs between sulfaquinoxaline sodium and sulfaquinoxaline 
sodium impurity. At pH of 6.0, baseline separation was achieved between sulfaquinoxaline 
sodium and its impurity and between sulfaquinoxaline sodium impurity and vitamin K3 but 
the Rs values were 1.8 and 1.7, respectively. 
 
At pH of 5.7, excellent separation was achieved between all the combined drugs as well as 
the impurity. When the pH was raised by 0.3 and 0.8 increments namely at 6.0 and 6.5 
respectively, the Rs 1.4 were 1.78 and 1.7, respectively and Rs 2.4 were 1.7 and 1.6, 
respectively. At pH of 7.0, complete interference occurred between sulfaquinoxaline 
sodium and its related impurity.  
 
Therefore, pH 5.7 was selected as optimum value to which a maximum Rs was achieved 
for all the combined drugs as shown in figure 4.7 and table 4.2.  
 
This behavior may happen because when the mobile phase pH increased significantly, 
more surface silanol groups of the stationary phase were deprotonated (-Si-O-). The 
electrostatic interactions between the positively charged basic compounds and negatively 
charged surface silanol groups increased resulting in increase of retention time of 
compounds.  
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Figure (4.7): Chromatograms obtained upon 20µl injection of a mixture of 
sulfaquinoxaline sodium (1), Vitamin K3 (2), and amprolium hydrochloride (3). Mobile 
phase consisting of ACN and NH4AC solution (80:20; v/v), at different pH’s; flow rate 0.5 
ml/min; λ =263nm. Note: peak (4) is due to sulfaquinoxaline sodium impurity. 
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Table (4.2):     Effect of pH on resolution (Rs) 
 
pH *Rs 1.4 †Rs 2.4 ‡Rs1.2 ζRs 2.3 
3.5 0 0 1.74 7.89 
4.0 0 0 4.35 5.6 
4.5 2.3 2.8 4.5 1.47 
5.7 2.14 2.2 3.9 7.3 
6.0 1.78 1.72 3.4 7.2 
6.5 1.7 1.6 3.3 7.6 
7.0 0 0 2.7 7.2 
 
*Rs 1.4: Represents the resolution value between sulfaquinoxaline sodium (1) and its 
impurity (4). 
†Rs 2.4 : Represents the resolution value between vitamin K3 (2) and sulfaquinoxaline 
sodium Impurity (4) 
‡Rs1.2 : Represents the resolution value between sulfaquinoxaline sodium (1) and vitamin 
K3 (2). 
ζ Rs 2.3: Represents the resolution value between vitamin K3 (2) and amprolium HCl (3) 
 
4.1.3. The effect of acetonitrile percentage: 
 
The effect of acetonitrile organic solvent percentage on Rs was also investigated. The 
ACN percentages combined with 0.2 M NH4AC aqueous buffer were 60, 70, 80, 85, 90, 
and 95% ACN.  It was found that increasing the ACN ratio increased the retention time 
and improved the Rs. The best Rs value was achieved by using 85%as shown in figure 4.8 
and table 4.3.  
 
When the ACN was 60%, interference occurred between sulfaquinoxaline sodium and its 
impurity and the Rs were decreased for all compounds. Analysis time was about 11 
minutes. At this point, it was anticipated that increasing the ACN concentration could 
improve the baseline separation and increase the Rs values between all compounds. 
Therefore, a systematic increase was tried with increment of 10% and 5%. When a 70% 
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ACN was tested, a better baseline separation achieved but still not satisfactory, when the 
ACN increased to 80%, a better separation was achieved. In all cases the pH was fixed to 
5.7. 
 
When 85% ACN was used at pH of 5.7, a separable four peaks was seen with a better 
resolution. At 90% ACN, the chromatogram reveals the best Rs values between 
sulfaquinoxaline sodium and its impurity with a total analysis time of about 23 minutes. 
The main drawback was the high value of analysis time which means it is time consuming. 
Finally, upon switching to 95% the last eluting peaks merged together as shown in the 
figure. Table 4.3 and figure 4.8 shows that the optimized mobile phase prepared from that 
system for the separation of all compounds was 0.2 M NH4AC: ACN (15:85; v/v), at pH of 
5.7. 
 
Figure 4.8 illustrates the change of retention time with varying ratios of ACN from 60-
95%. The results show that the content of ACN in the mobile phase has great influence on 
the resolution and selectivity. By increasing the %ACN, the polarity of the mobile phase 
decreased and the hydrophilic interactions between the analytes and the stationary were 
promoted, thereby dramatically increasing the retention of compounds. Our results 
indicated that the retention time was primarily governed by typical hydrophilic and 
electrostatic interactions between the solutes and the stationary phase. 
The effect of acetonitrile on retention was systematically behaved up to 90% ACN level. 
However, when an extra 5% ACN was added, the peak of vitamin K3 was eluted in close 
proximity to amprolium HCl.  This probably indicates a sudden change in equilibrium of 
this peak in the HILIC system.  
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Table (4.3): Effect of acetonitrile percentage on the resolution values of compounds 
separated   
% ACN *Rs 1.4 †Rs 2.4 ‡Rs1.2 ζRs 2.3 
60 0 0 2.04 3.7 
70 2.2 1.0 2.6 4.7 
80 2.1 2.1 3.5 7.15 
85 2.2 3.3 5.0 10.2 
90 2.5 6.2 7.8 8.8 
95 3.97 21.1 21.5 1.05 
 
*Rs 1.4: Represents the resolution value between sulfaquinoxaline sodium (1) and its 
impurity (4). 
†Rs 2.4 : Represents the resolution value between vitamin K3 (2) and sulfaquinoxaline 
sodium Impurity (4) 
‡Rs1.2 : Represents the resolution value between sulfaquinoxaline sodium (1) and vitamin 
K3 (2). 
ζ Rs 2.3: Represents the resolution value between vitamin K3 (2) and amprolium HCl (3) 
 
It is worthwhile mentioning that during the whole work, we chose to use Rs value as the 
chromatographic parameter since it reflects the column efficiency and selectivity. The 
relation between the three parameters is as shown below: 
 
N: Number of theoretical plates 
α: Selectivity factor  
KB: Capacity factor for compound B 
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Figure (4.8): The separation obtained with 20µl injection of a mixture of sulfaquinoxaline 
sodium (1), Vitamin K3 (2), and amprolium hydrochloride (3), Sulfaquinoxaline impurity 
(4). Mobile phase consisting of ACN and 0.2M NH4AC solution, at pH of 5.7; flow rate 
0.5 ml/min; λ =263nm. The %ACN is as shown in the figure.  
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4.1.4. The effect of methanol percentage: 
 
This time, we tried to use methanol (MeOH) in addition to ACN as organic solvent 
modifier by using different percentages of MeOH with ACN and constant buffer 
concentration of 0.2 M NH4AC (10:75:15; v/v/v) at pH of 5.7. We found that by using 
10% methanol, there is no significant effect on Rs values of all compounds as shown in 
figure 4.9 and table 4.4. By increasing the % MeOH up to 20%, we observed an increase in 
the resolution value between sulfaquinoxaline sodium and its impurity. We also observed a 
decrease in the Rs values between sulfaquinoxaline sodium impurity and vitamin K3 and 
between vitamin K3 and amprolium hydrochloride. The total analysis time was about 15 
minutes. 
 
At this stage, it was anticipated that using trinary solvent mixture, namely MeOH, ACN 
and buffer will either have no significant effect on the Rs of all compounds or would 
decrease the Rs since MeOH is stronger solvent compared to ACN using HILIC system 
and therefore may  decrease the retention time and Rs.  
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Figure (4.9): The separation obtained with 20µl injection of a mixture of sulfaquinoxaline 
sodium (1), Vitamin K3 (2), and amprolium hydrochloride (3), Sulfaquinoxaline impurity 
(4)  at mobile phase consisting of MeOH with ACN and  0.2 M NH4AC (10 :75 :15; v/v/v ) 
at pH of 5.7 and MeOH with ACN and  0.2 M NH4AC (20 :65 :15; v/v/v ) at pH of 5.7, 
respectively; flow rate 0.5 ml/min; λ =263nm. 
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Table (4.4):   Effect of adding methanol to mobile phase on resolution values 
 
%  MeOH *Rs 1.4 †Rs 2.4 ‡Rs1.2 ζRs 2.3 
0 2.2 3.3 5.0 10.2 
10 2.16 3.6 5.4 9.94 
20 2.9 2.55 5.0 5.3 
 
*Rs 1.4: Represents the resolution value between sulfaquinoxaline sodium (1) and its 
impurity (4). 
†Rs 2.4 : Represents the resolution value between vitamin K3 (2) and sulfaquinoxaline 
sodium Impurity (4) 
‡Rs1.2 : Represents the resolution value between sulfaquinoxaline sodium (1) and vitamin 
K3 (2). 
ζ Rs 2.3: Represents the resolution value between vitamin K3 (2) and amprolium HCl (3) 
 
 
1.4.5. The effect of temperature: 
 
The effect of the column temperature on the resolution and tailing factor was another 
chromatographic parameter that was studied during optimization of HPLC methods. 
Different temperatures such as 15°C, 20°C, 25°C, 30°C, were evaluated.  It was clear that 
varying temperatures between 15 °C and 30 °C have very little influence on Rs values as 
shown in figure 4.10 and table 4.5.  
The effect of temperature on the tailing factor was also determined. The best tailing factor 
obtained was at temperature of about 25°C and 30°C. 
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Figure (4.10): Chromatograms obtained upon 20µl injection of a mixture of 
sulfaquinoxaline sodium (1), Vitamin K3 (2), and amprolium hydrochloride (3), 
Sulfaquinoxaline impurity (4) at mobile phase consisting of ACN and 0.2M NH4AC 
solution (85:15; v/v) at pH 5.7; flow rate 0.5 ml/min; λ =263nm. The column temperature 
is as shown in the figure. 
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Table (4.5):    Effect of column temperature on resolution values  
 
Temperature 
(°C) 
*Rs 1.4 †Rs 2.4 ‡Rs1.2 ζRs 2.3 
15°C 2.0 2.9 4.7 9.6 
20°C 2.07 3.0 4.6 9.2 
25°C 2.2 2.6 4.3 10.1 
30°C 2.14 3.1 4.7 8.0 
 
*Rs 1.4: Represents the resolution value between sulfaquinoxaline sodium (1) and its 
impurity (4). 
†Rs 2.4 : Represents the resolution value between vitamin K3 (2) and sulfaquinoxaline 
sodium Impurity (4) 
‡Rs1.2 : Represents the resolution value between sulfaquinoxaline sodium (1) and vitamin 
K3 (2). 
ζ Rs 2.3: Represents the resolution value between vitamin K3 (2) and amprolium HCl (3) 
 
Table (4.6):    Effect of column temperature on tailing factor  
 
Temperature (°C) *TF(1) † TF (2) ‡TF (3) 
15°C 1.4 1.35 1.67 
20°C 1.35 1.33 1.54 
25°C 1.3 1.31 1.45 
30°C 1.3 1.29 1.48 
 
*TF (1): Represents the tailing factor of sulfaquinoxaline sodium (1)  
† TF (2): Represents the tailing factor of vitamin K3 (2)  
‡TF( 3): Represents the tailing factor of amprolium HCl  
 
 
 
 
53 
 
 
Tailing factor (TF): The tailing factor of a peak is calculated from the expression: [57] 
 
w0.05 = Width of the peak at one-twentieth of the peak height,   
d = Distance between the perpendicular dropped from the peak maximum and the leading 
edge of the peak at one-twentieth of the peak height.  
 
As shown from all the accumulated results, the optimized mobile phase consisted of a 
mixture of 0.2M NH4AC solution and ACN organic solvent (15:85; v/v); at pH 5.7 at room 
temperature. During the method development process, the concentration of the compounds 
prepared was about 20µg/ml of sulfaquinoxaline sodium, about 10µg/ml of Vitamin K3 , 
and about 20µg/ml of amprolium
 
hydrochloride. Figure 4.11 shows typical chromatograms 
obtained for individual components and for the mixture simultaneously using the 
optimized conditions. 
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Figure (4.11): Typical chromatograms obtained upon 20 µl separate injections of 
sulfaquinoxaline sodium, vitamin K3 and amprolium hydrochloride. Column, a ZIC-HILIC 
column (25.0 cm long ×4.6 mm i.d.) with particle size of 5 µm protected with a ZIC-HILIC 
guard column (20mm× 2.1mm, 5µm); Mobile phase consisting of  ACN and 0.2M NH4AC 
solution (85:15; v/v) at pH 5.7; flow rate 0.5 ml/min; λ =263nm; column 
temperature=25°C; Autosampler Temp. = 15°C. 
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Figure (4.12):  A typical chromatogram of mixture of sulfaquinoxaline sodium (1), 
vitamin K3 (2) and amprolium hydrochloride (3); Column, a ZIC-HILIC column (25.0 cm 
long ×4.6 mm i.d.) with particle size of 5 µm protected with a ZIC-HILIC guard column 
(20mm× 2.1mm, 5µm); Mobile phase consisting of  ACN and 0.2M NH4AC solution 
(85:15; v/v) at pH 5.7; flow rate 0.5 ml/min; λ =263nm; column temperature=25°C; 
Autosampler Temp. = 15°C. Note: Peak (4) is due to sulfaquinoxaline impurity. 
 
The concentration of compounds was monitored at 20µg/ml level for sulfaquinoxaline 
sodium, 0.2µg/ml for Vitamin K3, and 20µg/ml for amprolium hydrochloride to resemble 
the concentration ratio in the A.S.K product powder, Figure 4.13 shows typical 
chromatogram obtained for the mixture of these three compounds simultaneously using the 
optimized conditions.  
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Figure (4.13):  (A) typical chromatogram of mixture of sulfaquinoxaline sodium (1) 
(20µg/ml), vitamin K3 (2) (0.20µg/ml) and amprolium hydrochloride (3) (20µg/ml), Peak 
(4) is due to sulfaquinoxaline impurity. All other chromatographic conditions are same as 
in figure 4.12; (B) is a zoomed view of chromatogram A. 
 
 
A 
B 
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Chapter Five 
______________________________________________________ 
Analytical Validation of the Optimized HPLC Method 
______________________________________________________________________ 
 
The validation was carried out according to the ICH/USP guidelines and regulations. This 
chapter comprises the determination of the following validation parameters: Specificity; 
Linearity; Range; Accuracy (recovery); Precision (repeatability and intermediate 
precision); Robustness and Stress test. 
 
5.1 Specificity (placebo interference)  
 
The chromatograms of the placebo solution, standard solution and test solution were 
recorded at the same wavelength in order to check the specificity of the method, (See 
Figure 5.1). 
 
Assessment:  
No peaks were observed when the placebo (dextrose monohydrate) that lacks chromophore 
was injected. 
The retention time of the sulfaquinoxaline sodium, amprolium hydrochloride, and 
menadione (as sodium bisulfite) sample peaks match exactly to that of the appropriate 
peaks of the standard solution. No peaks are present at these retention times in the placebo 
chromatogram. Therefore, this method is suitable for the identification and the assay of 
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sulfaquinoxaline sodium, amprolium hydrochloride, and menadione (as sodium bisulfite) 
in A.S.K powder. 
 
 
Figure (5.1): A typical chromatograms of Placebo, standard solution of sulfaquinoxaline 
sodium, vitamin K3 and amprolium hydrochloride and test solution of A.S.K powder ; 
Column, a ZIC-HILIC column (25.0 cm long ×4.6 mm i.d.) with particle size of 5 µm 
protected with a ZIC-HILIC guard column (20mm× 2.1mm, 5µm); Mobile phase, 
acetonitrile and 0.2M ammonium acetate solution (15:85; v/v) adjusted to pH 5.7; flow rate 
0.5 ml/min; λ =263nm; column temperature=25°C; Autosampler Temp. = 15°C; 
concentration of vitamin K3 was about 0.2µg/ml.  
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Figure (5.2): A zoomed out  view chromatograms of Placebo, standard solution of 
sulfaquinoxaline sodium, vitamin K3 and amprolium hydrochloride and test solution of 
A.S.K powder ; Column, a ZIC-HILIC column (25.0 cm long ×4.6 mm i.d.) with particle 
size of 5 µm protected with a ZIC-HILIC guard column (20mm× 2.1mm, 5µm); Mobile 
phase, acetonitrile and 0.2M ammonium acetate solution (15:85; v/v) adjusted to pH 5.7; 
flow rate 0.5 ml/min; λ =263nm; column temperature=25°C; Autosampler Temp. = 15°C; 
concentration of vitamin K3 was about 0.2µg/ml.  
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5.2 Linearity 
 
Different amounts of sulfaquinoxaline sodium, amprolium hydrochloride and menadione 
(as sodium bisulfite) in the range of 60% to 130% of the labeled amount (5 concentration 
levels/ 3 replicates each) were added to A.S.K matrix (dextrose monohydrate). 
 
5.2.1. Linearity for sulfaquinoxaline sodium:  
 
The linearity for sulfaquinoxaline sodium in the range of 12µg/ml to 26µg/ml (60% to 
130% of the labeled amount) was investigated. Data and statistical evaluation are listed in 
table 5.1 and figure 5.3 
 
Table (5.1):  Linearity results and statistical evaluation for sulfaquinoxaline sodium 
in the range of 12µg/ml to 26µg/ml (60% to 130%)  
 
Sample peak area 
Conc. (µg/ml) 
Inj.1 Inj.2 Inj.3 Average 
12.0 7158529 7189186 7146490 7164735 
16.0 9567483 9574101 9652688 9613395 
20.0 11812875 11778166 11822609 11800388 
24.0 14318735 14280983 14374688 14327836 
26.0 15568277 15577638 15567050 15572344 
Average Area  11695739 
Statistical data for regression line 
Parameter Results A.C.* 
n* 15 ---- 
Coefficient of correlation 0.99973 Min. 0.995 
R2 0.9995 NLT 0.99 
Y-Intercept -11291= -0.1% < ± 2% of the average area 
Where, 
*n: number of determinations 
*A.C.: Acceptance criteria  
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Figure (5.3): The regression analysis of sulfaquinoxaline sodium over the range of 60% to 
130% of labeled amount (12µg/ml to 26µg/ml)  
 
Assessment: 
The regression line of sulfaquinoxaline sodium demonstrates linearity in the range of 60% 
to 130% (figure 5.3). The regression analysis (table 5.1) confirms that the deviation of the 
y-intercept from zero is not significant, the regression line is linear, R2 = 0.9995> 0.99 ; 
thus the method is linear in the range of 60% to 130% of the labeled amount, as shown in 
figure 5.3 and table 5.1. 
 
5.2.2. Linearity of Amprolium hydrochloride:  
 
The linearity for amprolium hydrochloride in the range of 12µg/ml to 26µg/ml (60% to 
130% of the labeled amount) was investigated. Data and statistical evaluation are listed in 
table 5.2 and figure 5.4  
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Table (5.2): Linearity results and statistical evaluation for amprolium hydrochloride 
in the range of 12µg/ml to 26µg/ml (60% to 130%)  
 
Sample peak area 
Conc. (µg/ml) 
Inj.1 Inj.2 Inj.3 Average 
12 3277273 3292404 3267086 3278921 
16 4359249 4363904 4364580 4364242 
20 5512413 5501599 5501665 5501632 
24 6502384 6505952 6516029 6510991 
26 7042134 7055996 7043506 7049751 
Average Area  5341107 
Statistical data for regression line 
Parameter Results A.C. 
n 15 ---- 
Coefficient of correlation 0.99981 Min. 0.995 
R2 0.9996 NLT 0.99 
Y-Intercept 62202 =  1.16 % < ± 2% of the average area 
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Figure (5.4): The regression analysis of amprolium hydrochloride over the range of 60% 
to 130% of labeled amount (12µg/ml to 26µg/ml)  
 
Assessment: 
The regression line of amprolium hydrochloride demonstrates linearity in the range of 60% 
to 130% (figure 5.4). The regression analysis (table 5.2) confirms that the deviation of the 
y-intercept from zero is not significant, the regression line is linear, R2 = 0.9996> 0.99; 
thus the method is linear in the range of 60% to 130% of the labeled amount, as shown in 
figure 5.4 and table 5.2. 
 
5.2.3. Linearity of Menadione (Vitamin K3):  
 
The linearity for menadione (as sodium bisulfite) in the range of 0.12µg/ml to 0.26µg/ml 
(60% to 130% of the labeled amount) was investigated. Data and statistical evaluation are 
listed in table 5.3 and figure 5.5  
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Table (5.3): Linearity results and statistical evaluation for menadione (as sodium 
bisulfite) in the range of 0.12µg/ml to 0.26µg/ml (60% to 130%) of labeled amount. 
 
Sample peak area 
Conc. (µg/ml) 
Inj.1 Inj.2 Inj.3 Average 
0.120 67453 67704 67507 67555 
0.160 87768 87861 87810 87836 
0.200 108379 106955 108130 107543 
0.240 132793 132358 133828 133093 
0.260 145865 145003 145638 145321 
Average Area  108269 
Statistical data for regression line 
Parameter Results A.C. 
n 15 ---- 
Coefficient of correlation 0.99833 NLT 0.995 
R2 0.9967 NLT 0.99 
Y-Intercept -644.34 = -0.6% < ± 2% of the average area 
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Figure (5.5): The regression analysis of menadione (as sodium bisulfite) over the range of 
60% to 130% of labeled amount (0.12µg/ml to 0.26µg/ml).  
 
Assessment: 
The regression line of menadione (as sodium bisulfite) demonstrates linearity in the range 
of 60% to 130% (figure 5.5). The regression analysis (table 5.3) confirms that the deviation 
of the y-intercept from zero is not significant, the regression line is linear, R2 = 0.9967> 
0.99; thus the method is linear in the range of 60% to 130% of the labeled amount, as 
shown in figure 5.5 and table 5.3. 
 
5.3 Range  
 
Considering the data for the regression line of sulfaquinoxaline sodium, amprolium 
hydrochloride, and menadione (as sodium bisulfite), linearity of each is given in the range 
of 60% to 130% of the labeled amount of final concentration.  
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5.4 Accuracy (recovery) 
 
The data obtained for the evaluation of the linearity were used. In all the experiments for 
accuracy test, the different concentrations of the components mixture were added to 
placebo matrix and the accuracy was measured as reflected by recovery as shown in the 
below formula:  
 
 
 
5.4.1. Accuracy (recovery) for sulfaquinoxaline sodium: 
 
The data obtained for the evaluation of the linearity were used. The accuracy as reflected 
from recovery data and statistical evaluation for assay of sulfaquinoxaline sodium over the 
range of 12µg/ml to 26µg/ml (60% to 130% of the specified final concentration) is listed in 
table 5.4. 
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Table (5.4): Recovery data and statistical evaluation of sulfaquinoxaline sodium over 
the range of 60% to 130% of the labeled amount of final concentration  
 
Concentration 
level % 
1st Value (%) 2nd Value (%) 3rd Value (%) 
60 99.2 99.5 99.0 
80 99.4 99.5 100.3 
100 98.2 97.9 98.3 
120 99.2 98.9 99.6 
130 99.5 99.6 99.5 
Statistical data 
Parameter Results A.C. * 
n 15 ----- 
X  99.2 96.0-104.0% 
S.D. 0.63 ----- 
C.V. (%) 0.63 <  2.0 
*C.I.  (P=95%) 98.8% to 99.6%  96.0-104.0% 
 
*C.I.: Confidence interval of the average value (P=95%) and is calculated by the 
following formula: 
 
 
X : The average of recovery values  
t: A parameter that depends upon the number of degrees of freedom and the confidence 
level required. 
S.D.: Standard deviation 
n: Number of determinations  
 
Assessment: 
The recovery shows results between 97.9% and 100.3 with coefficient of variation of 0.63 
%. The acceptance criteria are fulfilled. 
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5.4.2. Accuracy (recovery) for amprolium hydrochloride: 
 
The data obtained for the evaluation of the linearity were used. The recovery data and 
statistical evaluation for assay of amprolium hydrochloride over the range of 12µg/ml to 
26µg/ml (60% to 130% of the specified final concentration) are listed in table 5.5. 
 
Table (5.5): Recovery data and statistical evaluation of amprolium hydrochloride 
over the range of 60% to 130% of the labeled amount of final concentration  
 
Concentration 
level % 
1st Value (%) 2nd Value (%) 3rd Value (%) 
60 98.9 99.3 98.6 
80 98.6 98.7 98.8 
100 99.8 99.6 99.6 
120 98.1 98.1 98.3 
130 98.1 98.2 98.1 
Statistical data 
Parameter Results A.C. 
n 15 ----- 
X  99.0 96.0-104.0% 
S.D. 0.59 ----- 
C.V. (%) 0.6 <  2.0 
C.I.  (P=95%) 98.7% to 99.3%  96.0-104.0% 
 
Assessment: The recovery shows results between 98.1% and 99.8% with coefficient of 
variation of 0.6%. The acceptance criteria are fulfilled.  
 
5.4.3. Accuracy (recovery) for menadione (as sodium bisulfite):  
 
The data obtained for the evaluation of the linearity were used. The recovery data and 
statistical evaluation for assay of amprolium hydrochloride over the range of 0.12µg/ml to 
0.26µg/ml (60% to 130% of the specified final concentration) are listed in table 5.6. 
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Table (5.6): Recovery data and statistical evaluation of menadione (as sodium 
bisulfite) over the range of 60% to 130% of the labeled amount of final concentration  
 
Concentration 
level % 
1st Value (%) 2nd Value (%) 3rd Value (%) 
60 101.9 102.3 102.0 
80 99.5 99.6 99.5 
100 98.3 97.0 98.0 
120 100.3 100.0 101.1 
130 101.7 101.1 101.6 
Statistical data 
Parameter Results A.C. 
n 15 ----- 
X  100.3 96.0-104.0% 
S.D. 1.61 ----- 
C.V. (%) 1.61 <  3.0 
C.I.  (P=95%) 99.4% to 101.2%  96.0-104.0% 
 
Assessment:  
The recovery shows results between 97.0 % and 102.3% with coefficient of variation of 
1.61 % .The acceptance criteria are fulfilled. 
 
5.5 Precision  
 
5.5.1. Precision of sulfaquinoxaline sodium: 
 
5.5.1.1. Repeatability: 
 
One laboratory analyst carried out the assay of sulfaquinoxaline sodium on six 
determinations of homogeneous sample of A.S.K powder Batch Number: F01211ER at 
100% of the test concentration with the same analytical equipment at the same day. The 
results are listed on table 5.7.  
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Table (5.7):  Assay results and Statistical evaluation for repeatability of 
sulfaquinoxaline sodium in A.S.K powder Batch Number: F01211ER  
 
n=6 Assay of sulfaquinoxaline sodium (%) 
1 98.36 
2 99.22 
3 99.07 
4 99.14 
5 97.52 
6 99.66 
Statistical data 
Parameter Results A.C. 
X  98.83 90.0 -110% 
S.D. 0.76 ---- 
C.V. (%) 0.77 ≤ 2 % 
C.I. (P=95%) 98.0% to 99.7%  96.0-104.0% 
 
Assessment: The coefficient of variation of 0.77 % shows that the results of the HPLC 
assay procedure for determining sulfaquinoxaline sodium is within a suitable repeatability 
for the specified range. The acceptance criteria are fulfilled.  
 
5.5.1.2. Intermediate Precision (ruggedness): 
 
Two laboratory analysts carried out the assay of sulfaquinoxaline sodium on 12 
homogeneous samples of A.S.K powder at 100% of the final test concentration, with 
different analytical equipments at different days. The results are listed on table 5.8.  
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Table (5.8):  Assay results and Statistical evaluation for intermediate precision of 
sulfaquinoxaline sodium in A.S.K powder Batch Number: F01211ER   
 
n=12 1st assay of Sulfaquinoxaline 
sodium 
2nd assay of 
Sulfaquinoxaline sodium 
1 98.36 97.67 
2 99.22 97.89 
3 99.07 98.77 
4 99.14 97.69 
5 97.52 99.13 
6 99.66 98.80 
Statistical data 
Parameter Results A.C. 
X  98.58 90.0 -110% 
S.D. 0.71 ---- 
C.V. (%) 0.72 ≤ 3 % 
C.I. (P=95%) 98.1% to 99.0%  96.0-104.0% 
 
Assessment: 
The coefficient of variation of 0.72% shows that the results of the HPLC assay procedure 
for determining sulfaquinoxaline sodium is within a suitable intermediate precision for the 
specified range. The acceptance criteria are fulfilled.  
 
5.5.2. Precision of amprolium hydrochloride:  
 
5.5.2.1. Repeatability: 
 
One laboratory analyst carried out the assay of amprolium hydrochloride on six 
determinations of homogeneous sample of A.S.K powder at 100% of the test concentration 
with the same analytical equipment at the same day. The results are listed on table 5.9.  
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Table (5.9): Assay results and Statistical evaluation for repeatability of amprolium 
hydrochloride in A.S.K powder Batch Number: F01211ER  
 
n=6 Assay of amprolium hydrochloride (%) 
1 99.37 
2 99.38 
3 99.89 
4 100.24 
5 99.50 
6 101.04 
Statistical data 
Parameter Results A.C. 
X  99.90 90.0 -110% 
S.D. 0.65 ---- 
C.V. (%) 0.65 ≤ 2 % 
C.I.  (P=95%) 99.2% to 100.6%  96.0-104.0% 
 
Assessment:  
The coefficient of variation of 0.59 % shows that the results of the HPLC assay procedure 
for determining amprolium hydrochloride is within a suitable repeatability for the specified 
range. The acceptance criteria are fulfilled.  
 
 
5.5.2.2. Intermediate Precision (ruggedness): 
 
Two laboratory analysts carried out the assay of amprolium hydrochloride on 12 
homogeneous samples of A.S.K powder at 100% of the final test concentration, with 
different analytical equipments at different days. The results are listed on table 5.10.  
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Table (5.10):  Assay results and Statistical evaluation for intermediate precision of 
amprolium hydrochloride assay in A.S.K powder Batch Number: F01211ER 
 
n=12 1st assay of Amprolium 
hydrochloride 
2nd assay of Amprolium 
hydrochloride 
1 99.37 101.76 
2 99.38 101.26 
3 99.89 101.67 
4 100.24 100.53 
5 99.50 102.24 
6 101.04 101.07 
Statistical data 
Parameter Result A.C. 
X  100.66 90.0 -110% 
S.D. 0.624 ---- 
C.V. (%) 0.62 ≤ 3 % 
C.I. (P=95%) 100.3% to 101.1%  96.0-104.0% 
 
Assessment:  
The coefficient of variation 0.62 % shows that the results of the HPLC assay procedure for 
determining amprolium hydrochloride is within a suitable intermediate precision for the 
specified range. The acceptance criteria are fulfilled.  
 
5.5.3. Precision of menadione (as sodium bisulfite):   
 
5.5.3.1. Repeatability: 
 
One laboratory analyst carried out the assay of menadione on six determinations of 
homogeneous sample of A.S.K powder at 100% of the test concentration with the same 
analytical equipment at the same day.  The results are listed on table 5.11.  
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Table (5.11):  Assay results and Statistical evaluation for repeatability of menadione 
in A.S.K powder Batch Number: F01211ER 
  
n=6 Assay of menadione (%) 
1 97.70 
2 101.48 
3 101.11 
4 102.70 
5 97.94 
6 98.59 
Statistical data 
Parameter Result A.C. 
X  99.92 90.0 -110% 
S.D. 2.1 ---- 
C.V. (%) 2.1 ≤ 3 % 
C.I. (P=95%) 97.5% to 102.4%  96.0-104.0% 
 
Assessment: 
The coefficient of variation of 2.1 % shows that the results of the HPLC assay procedure 
for determining menadione is within a suitable repeatability for the specified range. The 
acceptance criteria are fulfilled.  
 
5.5.3.2. Intermediate Precision (ruggedness): 
 
Two laboratory analysts carried out the assay of menadione on 12 homogeneous samples 
of A.S.K powder at 100% of the final test concentration, with different analytical 
equipments at different days. The results are listed on table 5.12.  
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Table (5.12): Assay results and Statistical evaluation for intermediate precision of 
menadione in A.S.K powder Batch Number: F01211ER  
  
Number of determination 
n=12 
1st assay of Menadione 2nd assay of Menadione 
1 97.70 98.87 
2 101.48 100.03 
3 101.11 100.52 
4 102.70 99.01 
5 97.94 100.81 
6 98.59 100.91 
Statistical data 
Parameter Result A.C. 
X  99.97 90.0 -110% 
S.D. 1.5 ---- 
C.V. (%) 1.5 ≤ 3 % 
C.I. (P=95%) 99.0% to 100.9%  96.0-104.0% 
 
 
Assessment: 
The coefficient of variation 1.5 % shows that the results of the HPLC assay procedure for 
determining menadione is within a suitable intermediate precision for the specified range. 
The acceptance criteria are fulfilled.  
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5.6 Robustness  
 
5.6.1. Stability of standard & sample solution: 
 
5.6.1.1. Stability of the standard solution (stored at 15°C): 
 
The stability of the standard solution at temperature of 15°C stored in closed volumetric 
flask protected from light during a period of 24 hours is investigated. Data and statistical 
evaluation are listed in table 5.13. 
 
Table (5.13): Results and statistical evaluation of the assay of sulfaquinoxaline 
sodium, amprolium hydrochloride and menadione standard solution during a period 
of 24 hours. 
 
Time 
(Hours) 
sulfaquinoxaline 
sodium (Av.PAV) 
amprolium hydrochloride 
(Av.PAV) 
Menadione 
(Av.PAV) 
0 11961069.33 5526863.333 111602.3333 
24 12008352.00 5485563.667 112757.3333 
Statistical data 
Parameter sulfaquinoxaline 
sodium 
amprolium hydrochloride Menadione 
 
n 2 2 2 
X  11984710.67 5506213.5 112179.8333 
∆Av.PAV
 
*100 0.4 % 0.8% 1.0% 
A.C. ≤2.0% ≤2.0% ≤3.0% 
 
*∆Av.PAV : The difference between average peak area value after 24 hours and at 0 time 
divided by average peak area at 0 time. 
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Assessment: 
The Av. PAV of sulfaquinoxaline sodium, amprolium hydrochloride and menadione 
remained stable. Therefore the standard solution can be stored during a period of 24 hours 
at the temperature 15°C for the assay test. 
 
5.6.1.2. Stability of the sample solution (stored 15°C): 
The stability of the sample solution at temperature of 15°C stored in closed volumetric 
flask protected from light during a period of 24 hours is investigated. Data and statistical 
evaluation are shown in table 5.14.  
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Table (5.14): Results and statistical evaluation for the assay of sulfaquinoxaline 
sodium, amprolium hydrochloride and menadione sample solution during a period of 
24 hours. 
 
Time 
(Hours) 
sulfaquinoxaline 
sodium (Av.PAV) 
amprolium 
hydrochloride 
(Av.PAV) 
Menadione 
(Av.PAV) 
0 11870856 5626206.5 105886 
24 11785329.5 5593480.5 106162 
Statistical data 
Parameter sulfaquinoxaline 
sodium 
amprolium 
hydrochloride 
Menadione 
 
n 2 2 2 
X  11828092.75 5609843.5 106024 
∆Av.PAV
 
*100 
0.7 % 0.6% 0.3% 
A.C. ≤3.0% ≤3.0% ≤3.0% 
 
Assessment: 
The Av. PAV of sulfaquinoxaline sodium, amprolium hydrochloride and menadione 
remained stable. Therefore the sample solution can be stored during a period of 24 hours at 
the temperature 15°C for the assay test. 
 
5.6.2. Different ammonium acetate buffer percent in mobile phase: 
The sample and standard using different buffer percentages in the mobile phase (-3.0, +3.0) 
and normal % value was investigated. The results are listed in Table 5.15. 
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Table (5.15): Assay results and statistical evaluation for sulfaquinoxaline sodium, 
amprolium hydrochloride and menadione using different % of buffer in mobile phase 
(-3.0, +3.0) and normal % value. 
 
Mobile phase 
variation(v/v) 
ACN/0.2M 
ammonium acetate 
% Assay of 
sulfaquinoxaline 
sodium 
% Assay of 
amprolium 
hydrochloride 
 
% Assay of 
menadione 
 
88:12 99.3 99.9 101.5 
85:15 101.6 101.3 102.6 
82:18 101.4 101.9 101.3 
Statistical data 
Parameter sulfaquinoxaline 
sodium 
amprolium 
hydrochloride 
Menadione 
 
n 3 3 3 
X  100.8 101.0 101.8 
S.D. 1.27 1.03 0.7 
C.V. (%) 1.26 1.02 0.7 
A.C. ≤2.0% ≤2.0% ≤3.0% 
 
Assessment: Variation of ammonium acetate buffer in the range of (± 3 of the nominal 
value) shows no significant change in the final assay results of each of the above three 
compounds. 
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5.6.3. Different column batches (lots): 
 
Two column batches filled with the prescribed stationary phases were investigated. The 
results are listed in Table 5.16. 
  
Table (5.16): Assay results and statistical evaluation for sulfaquinoxaline sodium, 
amprolium hydrochloride and menadione using two different column batches 
 
Column batch 
Number 
% Assay of 
sulfaquinoxaline 
sodium 
% Assay of 
amprolium 
hydrochloride 
% Assay of 
menadione 
 
L010134877 101.6 101.5 101.3 
L010129977 101.6 101.3 102.6 
Statistical data 
Parameter sulfaquinoxaline 
sodium 
amprolium 
hydrochloride 
Menadione 
 
n 2 2 2 
X  101.6 101.4 101.95 
S.D. 0 0.4 0.9 
C.V. (%) 0 0.4 0.9 
A.C. ≤2.0% ≤2.0% ≤3.0% 
 
Assessment: 
Using different column batches shows no significant change in the final assay results of 
each of the above three compounds. 
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5.6.4. Variations of the column temperature: 
 
Three different column temperatures were investigated in the range 23-27°C. The results 
are listed in table 5.17. 
 
Table (5.17): Assay results and statistical evaluation for sulfaquinoxaline sodium, 
amprolium hydrochloride and menadione using different column temperatures  
 
Column Temp. ( °C) % Assay of 
sulfaquinoxaline 
sodium 
% Assay of 
amprolium 
hydrochloride 
% Assay of 
menadione 
 
23 99.6 99.9 100.0 
25 101.6 101.5 101.3 
27 100.2 100.9 100.6 
Statistical data 
Parameter sulfaquinoxaline 
sodium 
amprolium 
hydrochloride 
Menadione 
 
n 3 3 3 
X  100.3 100.8 100.6 
S.D. 1.02 0.8 0.65 
C.V. (%) 1.02 0.8 0.64 
A.C. ≤2.0% ≤2.0% ≤3.0% 
 
Assessment: 
Using different column temperatures in the range of 23-27°C shows no significant change 
in the final assay results of each of the above three compounds. 
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5.6.5. Use of Different flow rates: 
 
Different mobile phase flow rates of 0.45, 0.50, and 0.55 ml/min. were investigated. The 
results are shown in Table 5.18. 
  
Table (5.18): Assay results and statistical evaluation for sulfaquinoxaline sodium, 
amprolium hydrochloride and menadione using three different flow rates. 
 
F.R. (ml/min) % Assay of 
sulfaquinoxaline 
sodium 
% Assay of 
amprolium 
hydrochloride 
% Assay of 
menadione 
 
0.45 100.57 100.97 99.5 
0.50 101.6 101.5 101.3 
0.55 100.45 100.51 100.50 
Statistical data 
Parameter sulfaquinoxaline 
sodium 
amprolium 
hydrochloride 
Menadione 
 
n 3 3 3 
X  100.87 101.0 100.43 
S.D. 0.6 0.5 0.9 
C.V. (%) 0.6 0.5 0.9 
A.C. ≤2.0% ≤2.0% ≤3.0% 
 
Assessment: 
Using different flow rates in the range of 0.45 to 0.55 ml/min. shows no significant change 
in the final assay results of each of the above three compounds. 
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5.6.6. Variation of mobile phase pH values: 
Three different pH values of the mobile phase (5.6, 5.7, and 5.8) were investigated. The 
results are listed in Table 5.19. 
 
Table (5.19): Assay results and statistical evaluation for sulfaquinoxaline sodium, 
amprolium hydrochloride and menadione using three different mobile phase pH 
values 
 
pH % Assay of 
sulfaquinoxaline 
sodium 
% Assay of 
amprolium 
hydrochloride 
% Assay of 
menadione 
 
5.6 101.96 100.44 101.12 
5.7 100.6 101.34 101.42 
5.8 101.33 101.14 100.16 
Statistical data 
Parameter sulfaquinoxaline 
sodium 
amprolium 
hydrochloride 
Menadione 
 
n 3 3 3 
X  101.3 100.97 100.9 
S.D. 0.7 0.5 0.7 
C.V. (%) 0.7 0.5 0.7 
A.C. ≤2.0% ≤2.0% ≤3.0% 
 
Assessment: 
Using mobile phase pH in the range of 5.7 ± 0.1 shows no significant change in the final 
assay results of each of the above three compounds. 
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5.7 Stress Tests 
 
The excipients and active substances were submitted to acidic, basic, oxidizing, light and 
dry heat forced degradation conditions. Samples were analyzed by HPLC to proof the 
stability indicating capability. The degradation peaks detected in the chromatogram using 
the HPLC method are completely separated and no interference was detected whatever the 
stressed conditions are. 
One may also conclude that the method developed for determination of sulfaquinoxaline 
sodium, amprolium hydrochloride and menadione (as sodium bisulfite) is stability 
indicating and thus can be used for the determination of sulfaquinoxaline sodium, 
amprolium hydrochloride and menadione (as sodium bisulfite) in A.S.K powder for the 
control of the finished product and for the stability testing. 
 
5.7.1. Stress tests for excipient: 
Separate samples of the excipient (dextrose monohydrate) were treated as follows:  
 
The 1st sample: About 59.8 mg of the dextrose monohydrate is heated for 72 hours at 
105°C in an oven and then dissolved in 100 ml 90% ACN. Finally, 5 ml of this solution is 
diluted to 50 ml with mobile phase. 
The 2nd sample: About 59.8 mg of the dextrose monohydrate is mixed with 20 ml of 1 M 
HCl for 24 hours, neutralized with 1 M NaOH and then diluted to 100 ml with 90% ACN. 
Finally, 5 ml of this solution is diluted to 50 ml with mobile phase. 
The 3rd sample:  About 59.8 mg of the dextrose monohydrate is mixed with 20 ml of 1 M 
NaOH for 24 hours, neutralized with 1 M HCl and then diluted to 100 ml with 90% ACN. 
Finally, 5 ml of this solution is diluted to 50 ml with mobile phase. 
The 4th Sample: About 59.8 mg of the dextrose monohydrate is mixed with 95 ml of 3% 
H2O2 for 1 hour and then diluted to 100 ml with 90% ACN. Finally, 5 ml of this solution is 
diluted to 50 ml with mobile phase.  
The 5th sample: About 59.8 mg of the dextrose monohydrate is stressed under day light 
for 72 hours and then dissolved in 100 ml 90% ACN. Finally, 5 ml of this solution is 
diluted to 50 ml with mobile phase. 
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Figure 5.6 illustrates clearly that the excipient did not generate any degradation products 
under any of the above stress conditions except under H2O2 which give a peak with a 
retention time of about 10 minutes that is due to H2O2 and it is not due to degradation. 
  
 
Figure (5.6): Stress tests for excipient 
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5.7.2. Stress tests for sulfaquinoxaline sodium: 
 
5.7.2.1. Stress test with heat (105°C): 
 
20 mg of Sulfaquinoxaline sodium was heated for 72 hours at 105°C in an oven and then 
dissolved in 100 ml 90% ACN. Finally, 5 ml of this solution is diluted to 50 ml with 
mobile phase. 
 
Figure 5.7 illustrates clearly that sulfaquinoxaline sodium under heat stress conditions 
shows a slight increase of known potential degradation impurity with relative retention 
time (RRT) of about 1.2 related to sulfaquinoxaline sodium. It is worthwhile mentioning 
that this impurity is the very same impurity appeared in our A.S.K powder.  
 
Assessment: 
The potential degradation product (impurity) of the sulfaquinoxaline sodium was observed 
under stress test with heat. The degradation impurity is well separated from the 
sulfaquinoxaline sodium and other active ingredients. Peak (1) is sulfaquinoxaline and 
peak (2) is due to its impurity (sulfaquinoxaline impurity A).  
 
 
Figure (5.7): Stress test with heat for sulfaquinoxaline sodium 
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5.7.2.2. Stress test under oxidation: 
 
20 mg of sulfaquinoxaline sodium was mixed with 95 ml of 3% H2O2 for one hour and 
then diluted to 100 ml with 90% ACN. Finally, 5 ml of this solution is diluted to 50 ml 
with mobile phase.  
 
Figure 5.8 illustrates clearly that sulfaquinoxaline sodium under stress conditions with 3% 
H2O2 shows a slight increase of two potential degradation impurities with relative retention 
times (RRT) of 1.2 and 1.3 related to sulfaquinoxaline sodium. It is worthwhile mentioning 
that impurity with RRT of 1.2 is the very same impurity appeared in our A.S.K powder.  
 
Assessment: 
The potential degradation products (impurities) of the sulfaquinoxaline sodium were 
observed under stress test with oxidation. The degradation impurities are well separated 
from the sulfaquinoxaline sodium and other active ingredients. Peak (1) is sulfaquinoxaline 
and other peaks (2) and (3) are due to degradation impurities. Peak (4) with relative 
retention time of 1.7 is due to H2O2 (was observed in the placebo). 
 
 
 
Figure (5.8): Stress test under oxidation for sulfaquinoxaline sodium 
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5.7.2.3. Stress test with light: 
 
20 mg of sulfaquinoxaline sodium was stressed under day light for 72 hours and then 
dissolved in 100 ml 90% ACN. Finally, 5 ml of this solution is diluted to 50 ml with 
mobile phase. 
 
Figure 5.9 illustrates clearly that sulfaquinoxaline sodium under light stress conditions 
shows a slight increase of known potential degradation impurity (sulfaquinoxaline impurity 
A) with relative retention time of about 1.2 related to sulfaquinoxaline sodium.   
 
Assessment: 
The potential degradation product (impurity) of the sulfaquinoxaline sodium was observed 
under stress test with light. The degradation impurity is well separated from the 
sulfaquinoxaline sodium and other active ingredients. Peak (1) is sulfaquinoxaline and 
peak (2) is due to its impurity (sulfaquinoxaline impurity A).  
 
 
Figure (5.9): Stress test with light for sulfaquinoxaline sodium 
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5.7.2.4. Stress test with hydrochloric acid: 
 
20 mg of sulfaquinoxaline sodium was mixed with 20 ml of 1 M HCl for 24 hours, 
neutralized with 1M NaOH and then diluted to 100 ml with 90% ACN. Finally, 5 ml of 
this solution is diluted to 50 ml with mobile phase. 
 
Figure 5.10 illustrates clearly that sulfaquinoxaline sodium under stress conditions with 
HCl shows a slight increase of a known potential degradation impurity (sulfaquinoxaline 
impurity A) with a relative retention time of about 1.2 related to sulfaquinoxaline sodium.  
 
Assessment: 
The potential degradation product (impurity) of the sulfaquinoxaline sodium was observed 
under stress test with HCl. The degradation impurity is well separated from the 
sulfaquinoxaline sodium and other active ingredients. Peak (1) is sulfaquinoxaline and 
peak (2) is due to its impurity.  
 
 
 
Figure (5.10): Stress test with hydrochloric acid for sulfaquinoxaline sodium. 
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5.7.2.5. Stress test with Sodium Hydroxide: 
 
20 mg of sulfaquinoxaline sodium was mixed with 20 ml of 1 M NaOH for 24 hours, 
neutralized with 1M HCl and then diluted to 100 ml with 90% ACN. Finally, 5 ml of this 
solution is diluted to 50 ml with mobile phase. 
 
Figure 5.11 illustrates clearly that sulfaquinoxaline sodium under stress conditions with 
sodium hydroxide shows a slight increase of a known potential degradation impurity 
(sulfaquinoxaline impurity A) with relative retention time of about 1.2 related to 
sulfaquinoxaline sodium.   
 
Assessment: 
The potential degradation product (impurity) of the sulfaquinoxaline sodium was observed 
under stress test with NaOH. The degradation impurity is well separated from the 
sulfaquinoxaline sodium and other active ingredients. Peak (1) is sulfaquinoxaline and 
peak (2) is due to its impurity.  
 
 
 
Figure (5.11): Stress test with sodium hydroxide for sulfaquinoxaline sodium 
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5.7.2. Stress tests for Menadione (as sodium bisulfite): 
 
5.7.2.1. Stress test with heat (105°C): 
 
32 mg menadione sodium bisulfite was heated for 72 hours at 105°C in an oven and then 
dissolved in 100 ml 90% ACN. Finally, 5 ml of this solution is diluted to 50 ml with 
mobile phase. 
 
Figure 5.12 illustrates clearly that menadione sodium bisulfite under heat stress conditions 
shows an increase on unknown potential degradation impurity with a relative retention 
time of about 0.65 related to menadione sodium bisulfite. 
 
Assessment: 
The potential degradation product (impurity) of the menadione sodium bisulfite was 
observed under stress test with heat. The degradation impurity is well separated from the 
menadione sodium bisulfite and other active ingredients. Peak (2) is the menadione and 
peak (1) is due to its impurity.  
 
 
Figure (5.12): Stress test with heat for menadione sodium bisulfite. 
 
 
 
92 
 
 
5.7.2.2. Stress test under oxidation: 
 
32 mg of menadione sodium bisulfite was mixed with 95 ml of 3% H2O2 for one hour and 
then diluted to 100 ml with 90% ACN. Finally, 5 ml of this solution is diluted to 50 ml 
with mobile phase.  
 
Figure 5.13 illustrates clearly that menadione sodium bisulfite under stress conditions with 
3% H2O2 did not show any potential degradation impurity. Peak (2) with relative retention 
time of 1.2 is due to H2O2 (was observed in the placebo). 
 
Assessment: 
No potential degradation products (impurities) of the menadione sodium bisulfite were 
observed under oxidation stress test. Peak (1) is the menadione and peak (2) is due to H2O2 
in placebo. 
 
 
 
Figure (5.13): Stress test under oxidation for menadione sodium bisulfite 
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5.7.2.3. Stress test with light: 
 
32 mg of menadione sodium bisulfite was stressed under day light for 72 hours and then 
dissolved in 100 ml 90% ACN. Finally, 5 ml of this solution is diluted to 50 ml with 
mobile phase. 
 
Figure 5.14 illustrates clearly that menadione sodium bisulfite under light stress conditions 
shows an increase on unknown potential degradation impurity with relative retention time 
of about 0.65 related to menadione sodium bisulfite.   
 
Assessment: 
The potential degradation product (impurity) of the menadione sodium bisulfite was 
observed under stress test with light. The degradation impurity is well separated from the 
menadione sodium bisulfite and other active ingredients. 
 
 
 
 
Figure (5.14): Stress test with light for menadione sodium bisulfite 
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5.7.2.4. Stress test with hydrochloric acid: 
 
32 mg of menadione sodium bisulfite was mixed with 20 ml of 1 M HCl for 24 hours, 
neutralized with 1M NaOH and then diluted to 100 ml with 90% ACN. Finally, 5 ml of 
this solution is diluted to 50 ml with mobile phase. 
 
Figure 5.15 illustrates clearly that menadione sodium bisulfite under stress conditions with 
HCl shows a slight increase on unknown potential degradation impurity with a relative 
retention time of about 0.65 related to menadione sodium bisulfite.   
 
Assessment: 
The potential degradation product (impurity) of the Menadione sodium bisulfite was 
observed under stress test with HCl. The degradation impurity is well separated from the 
menadione sodium bisulfite and other active ingredients. Peak (2) is the menadione and 
peak (1) is due to its impurity.  
 
 
Figure (5.15): Stress test with hydrochloric acid for menadione sodium bisulfite. 
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5.7.2.5. Stress test with Sodium Hydroxide: 
 
32 mg of menadione sodium bisulfite was mixed with 20 ml of 1 M NaOH for 24 hours, 
neutralized with 1M HCl and then diluted to 100 ml with 90% ACN. Finally, 5 ml of this 
solution is diluted to 50 ml with mobile phase. 
 
Figure 5.16 illustrates clearly that menadione sodium bisulfite under stress conditions with 
sodium hydroxide shows an increase of five unknown potential degradation impurities 
with relative retention times of about 0.65, 0.82, 0.87, 0.92, and 1.2 related to menadione 
sodium bisulfite. It was clear that NaOH destroyed the compound completely and no 
menadione peak was found.  
 
Assessment: 
The potential degradation products (impurities) of the menadione sodium bisulfite were 
observed under stress test with NaOH. The unknown degradation impurities are well 
separated from the menadione sodium bisulfite and other active ingredients.  
 
 
 
Figure (5.16): Stress test with sodium hydroxide for menadione sodium bisulfite 
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5.7.4. Stress tests for Amprolium hydrochloride: 
 
5.7.4.1. Stress test with heat (105°C): 
20 mg of amprolium hydrochloride was heated for 72 hours at 105°C in an oven and then 
dissolved in 100 ml 90% ACN. Finally, 5 ml of this solution is diluted to 50 ml with 
mobile phase. 
Figure 5.17 illustrates clearly that amprolium hydrochloride under heat stress conditions 
shows a slight increase on unknown potential degradation impurity with relative retention 
time of about 0.3 related to amprolium hydrochloride.    
 
Assessment: 
The potential degradation product (impurity) of the amprolium hydrochloride was 
observed under stress test with heat. The degradation impurity is well separated from the 
amprolium hydrochloride and other active ingredients. Peak (2) is the amprolium HCl and 
peak (1) is due to its impurity.  
 
 
Figure (5.17): Stress test with heat for amprolium hydrochloride. 
 
 
 
97 
 
 
5.7.4.2. Stress test under oxidation: 
 20 mg of amprolium hydrochloride was mixed with 95 ml of 3% H2O2 for one hour and 
then diluted to 100 ml 90% with ACN. Finally, 5 ml of this solution is diluted to 50 ml 
with mobile phase.  
Figure 5.18 illustrates clearly that amprolium hydrochloride under stress conditions with 
3% H2O2 did not show any potential degradation impurity. Peak (1) with relative retention 
time of 0.70 is due to H2O2 in placebo. 
 
Assessment: 
No potential degradation products (impurities) of the amprolium hydrochloride were 
observed under stress test with oxidation. Peak (2) is the amprolium hydrochloride and 
peak (1) is due to H2O2 in placebo. 
 
 
 
Figure (5.18): Stress test under oxidation for amprolium hydrochloride. 
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5.7.4.3. Stress test with light: 
 
20 mg of amprolium hydrochloride was stressed under day light for 72 hours and then 
dissolved in 100 ml 90% ACN. Finally, 5 ml of this solution is diluted to 50 ml with 
mobile phase. 
 
Figure 5.19 illustrates clearly that amprolium hydrochloride under light stress conditions 
shows a slight increase in an unknown potential degradation impurity with relative 
retention time of about 0.32 related to amprolium hydrochloride. 
 
Assessment: 
The potential degradation product (impurity) of the amprolium hydrochloride was 
observed under stress test with light. The degradation impurity is well separated from the 
amprolium hydrochloride and other active ingredients. Peak (2) is the amprolium HCl and 
peak (1) is due to its impurity.  
 
 
 
Figure (5.19): Stress test with light for amprolium hydrochloride. 
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5.7.4.4. Stress test with hydrochloric acid: 
 
20 mg of amprolium hydrochloride was mixed with 20 ml of 1 M HCl for 24 hours, 
neutralized with 1M NaOH and then diluted to 100 ml with 90% ACN. Finally, 5 ml of 
this solution is diluted to 50 ml with mobile phase. 
 
Figure 5.20 illustrates clearly that amprolium hydrochloride under stress conditions with 
HCl shows a slight increase on unknown potential degradation impurity with a relative 
retention time of about 0.37 related to amprolium hydrochloride 
 
Assessment: 
The potential degradation product (impurity) of the amprolium hydrochloride was 
observed under stress test with HCl. The degradation impurity is well separated from the 
amprolium hydrochloride and other active ingredients. Peak (2) is the amprolium HCl and 
peak (1) is due to its impurity.  
 
 
Figure (5.20): Stress test with hydrochloric acid for amprolium hydrochloride. 
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5.7.4.5. Stress test with Sodium Hydroxide: 
 
20 mg of amprolium hydrochloride was mixed with 20 ml of 1 M NaOH for 24 hours, 
neutralized with 1M HCl and then diluted to 100 ml with 90% ACN. Finally, 5 ml of this 
solution is diluted to 50 ml with mobile phase. 
 
Figure 5.21 illustrates clearly that amprolium hydrochloride under stress conditions with 
sodium hydroxide shows an increase on six unknown potential degradation impurities with 
relative retention times of about 0.38, 0.45, 0.50, 0.58, 0.69 and 0.94 related to amprolium 
hydrochloride. 
 
Assessment: 
The potential degradation products (impurities) of the Amprolium hydrochloride were 
observed under stress test with NaOH. The unknown degradation impurities are well 
separated from the amprolium hydrochloride.  However, there was an overlap between one 
of the degradation impurities and menadione. This seems to be inevitable since the NaOH 
completely destroyed the compound. No peak for amprolium HCl could be found.  
 
 
 
Figure (5.21): Stress test with sodium hydroxide for Amprolium hydrochloride. 
 
In case of amprolium hydrochloride degradation under sodium hydroxide, the degradation 
pathway is complex and the decomposition products may be only observed under forcing 
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conditions and are unlikely to be formed under accelerated or long term testing. Therefore 
it may not be necessary to examine specifically these degradation products since they are 
not formed in practice as we have seen upon carrying the test of accelerated testing at 40°C 
and 75% relative humidity for six months as recommended for the A.S.K powder product 
(i.e. sealed aluminum package).We did not observe any degradation for amprolium 
injected separately. [58] 
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Chapter Six 
______________________________________________________ 
Conclusion and Recommendations: 
________________________________________________________________________ 
 
The proposed optimized HPLC method described herein was evaluated over the linearity, 
precision, accuracy, specificity, ruggedness and robustness. The method proved to be 
convenient and effective for the quality control of sulfaquinoxaline sodium, vitamin K3 
sodium bisulfite, and amprolium hydrochloride in A.S.K powder. It does not suffer any 
positive or negative interference due to common excipient present in the formulation and 
can be conveniently used for routine quality control analysis. All the assay validation 
results were within the allowed specifications of ICH/USP guidelines. The proposed 
optimized method is rapid, selective, requires a simple sample preparation procedure, and 
represents a good procedure for the simultaneous determination of the combined drugs in 
A.S.K formulation.  
 
Moreover, this method is capable of distinguishing between the compounds of interest and 
their main degrades, which are expected to be present in the product since it passes the test 
of stability under stress conditions. 
   
A.S.K Powder is difficult to separate via typical reverse phase HPLC or ion-pair RP-
HPLC, but is readily separated by the ZIC®-HILIC column. This method is very sensitive 
and the assay can be performed only within 18 minutes.  
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Because of its novel column chemistry and unique selectivity, the ZIC-HILIC column 
allows excellent separation with faster analysis time, less organic solvent consumption and 
with no ion-pair reagent usage which make the routine analysis much cheaper. Reversal of 
elution order was noticed in comparison to RPLC mode. 
 
Good linearity was shown over the 12–26 µg/ml levels for sulfaquinoxaline sodium and 
amproliun HCl and over the 0.12–0.26 µg/ml levels for menadione Recovery was found to 
be within the acceptable criteria (96.0- 104.0%) for all compounds of interest along the 
linearity range.  
 
Recommendations: 
 
1.) As seen some components of the product is affected greatly with heat especially 
menadione so the prepared solution is best to be kept in refrigerator in a closed 
container if need to be used for long time or prepared fleshly or either to be kept at 
15°C for 24 hours as shown in solution stability. 
2.) The product must be protected form sodium hydroxide since it destroy ed 
completely some of the product components. 
3.) The assay needs to be used to compare the innovative product to the one from 
Pharmacare in order to establish similarity required for the product registration 
4.) Specifications need to be set for the product to pass 
5.) The assay may be used to determine the best conditions for the farmers to prepare 
the formulation. For example, the introduction mentioned that they prepare in water 
and dose for three days followed by an additional 3 days with a break in between. 
Can a farmer prepare one batch and use it for the whole treatment period or is it 
better to prepare for each day. This will depend on the stability. 
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 ٣ﻙﻨﻭﻝﻴﻥ ﺼﻭﺩﻴﻭﻡ ، ﻭﻓﻴﺘﺎﻤﻴﻥ ﻴ ﻤﺭﻜﺒﺎﺕ ﺍﻝﺴﻠﻔﺎﻜﻭﻝﺘﺤﻠﻴل ﻓﻌﺎﻝﻪﻭ ﺠﺩﻴﺩﺓ ﺔ ﻁﺭﻴﻘﺘﻁﻭﻴﺭ :ﺍﻝﻌﻨﻭﺍﻥ
 ﻓﻲ ﺍﻝﻤﺴﺘﺤﻀﺭ ﺍﻝﺒﻴﻁﺭﻱ ﻤﻌﺎ ﻤﺠﺘﻤﻌﺔ ﺴﻠﻔﺎﻴﺕ ، ﻭﺍﻻﻤﺒﺭﻭﻝﻴﻭﻡ ﻫﻴﺩﺭﻭﻜﻠﻭﺭﺍﻴﺩﺍﻝ  ﺜﻨﺎﺌﻲﺼﻭﺩﻴﻭﻡ
  ﺸﺭﻜﺔ ﺩﺍﺭ ﺍﻝﺸﻔﺎﺀﻭﺍﻝﻤﺼﻨﻊ ﻓﻲ K.S.A
 
  . ﻏﺎﻨﻡﺇﺴﻤﺎﻋﻴلﻓﺭﻴﺩ  ﻤﺸﻬﻭﺭ ﻤﺤﻤﺩ :ﺍﻝﻁﺎﻝﺏ ﺇﻋﺩﺍﺩ
 
 .ﺒﻭ ﻻﻓﻲﺃﺼﺎﻝﺢ  : ﺭ ﺍﻝﺩﻜﺘﻭﺇﺸﺭﺍﻑ
  
  :ﻤﻠﺨﺹ
 ٣ﻙ، ﻭﻓﻴﺘـﺎﻤﻴﻥ (١)ﻨﻭﻝﻴﻥ ﺼﻭﺩﻴﻭﻡ ﻴ ﻝﺘﺤﻠﻴل ﻤﺭﻜﺒﺎﺕ ﺍﻝﺴﻠﻔﺎﻜﻭ ﺠﺩﻴﺩﺓﻴﺘﻨﺎﻭل ﻫﺫﺍ ﺍﻝﺒﺤﺙ ﺘﻘﺩﻴﻡ ﻁﺭﻴﻘﺔ 
 K.S.Aﻓﻲ ﺍﻝﻤﺴﺘﺤﻀﺭ ﺍﻝﺒﻴﻁـﺭﻱ ( ٣)، ﻭﺍﻻﻤﺒﺭﻭﻝﻴﻭﻡ ﻫﻴﺩﺭﻭﻜﻠﻭﺭﺍﻴﺩ (٢)ﺴﻠﻔﺎﻴﺕ ﺍﻝ  ﺜﻨﺎﺌﻲ ﺼﻭﺩﻴﻭﻡ
  .ﺍﻝﻤﻭﺠﻭﺩ ﻋﻠﻰ ﺸﻜل ﺒﻭﺩﺭﺓ
ﺘﻭﻏﺭﺍﻓﻴﺎ ﺍﻝﺴﺎﺌﻠﺔ ﻭﻗﺩ ﺍﺴـﺘﺨﺩﻡ ﺍﻝﻌﻤـﻭﺩ ﺍﻝﻜﺭﻭﻤـﺎﺘﻭﻏﺭﺍﻓﻲ ﺘﻤﺕ ﻋﻤﻠﻴﺔ ﺍﻝﻔﺼل ﺒﺎﺴﺘﺨﺩﺍﻡ ﺍﻝﻜﺭﻭﻤﺎ ﻝﻘﺩ 
 ﺍﺴـﻴﺘﺎﺕ  ﻤﺤﻠﻭل ﻤﻨﻅﻡ ﻤـﻥ ﻝﺘﺭ/ ﻤﻭل ٢,٠ ﺍﻝﻁﻭﺭ ﺍﻝﻤﺘﺤﺭﻙ ﻓﻜﺎﻥ ﻋﺒﺎﺭﺓ ﻋﻥ ﺃﻤﺎ (.CILIH-CIZ)
 Hp ﺩﺭﺠﺔ ﺍﻝﺤﻤﻭﻀﺔ ﻀﺒﻁﺕ، ﻭﻗﺩ ( ﻤل٠٥٨: ﻤل٠٥١)ﻭﻨﻴﺘﺭﻴل ﺘﺍﻻﻤﻭﻨﻴﻭﻡ ﻤﺫﺍﺏ ﻓﻲ ﻤﺎﺀ ﻨﻘﻲ ﻭﺍﺴﻴ 
  . ﻨﺎﻨﻭﻤﻴﺘﺭ٣٦٢ﺒﻁﺕ ﻁﻭل ﺍﻝﻤﻭﺠﺔ ﻋﻨﺩ  ﺍﻝﻤﺭﻜﺯ ﻭﻗﺩ ﻀﺍﻝﺨﻠﻴﻙ ﺒﺎﺴﺘﺨﺩﺍﻡ ﺤﻤﺽ ٧,٥ ﺍﻝﻘﻴﻤﺔ ﺇﻝﻰ
 ﻤﺜل ﺘﺭﻜﻴﺯ ﺍﻻﺴﻴﺘﻭﻨﻴﺭﻴل، ﺘﺭﻜﻴـﺯ ﺍﺴـﻴﺘﺎﺕ ﺍﻝﻔﻀﻠﻰﻝﻘﺩ ﺘﻡ ﺨﻼل ﻫﺫﺍ ﺍﻝﺒﺤﺙ ﺩﺭﺍﺴﺔ ﺍﻝﻅﺭﻭﻑ ﺍﻝﻌﻤﻠﻴﺔ 
 .ﺍﻻﻤﻭﻨﻴﻭﻡ، ﺩﺭﺠﺔ ﺍﻝﺤﻤﻭﻀﺔ ﻝﻠﻁﻭﺭ ﺍﻝﻤﺘﺤﺭﻙ ﻋﻠﻰ ﻋﻤﻠﻴﺔ ﺍﻝﻔﺼل ﻝﻠﻤﺭﻜﺒﺎﺕ ﺍﻝﺜﻼﺜﺔ
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 ﺍﻝﻁﺭﻴﻘﺔ ﻗﺩ ﺍﺠﺘـﺎﺯﺕ ﺠﻤﻴـﻊ ﺃﻥ ﺩﺭﺍﺴﺔ ﺍﻝﺘﺜﺒﺕ ﻝﻁﺭﻴﻘﺔ ﺍﻝﺘﺤﻠﻴل ﺒﻌﺩ ﺘﻁﻭﻴﺭﻫﺎ ﻭﻗﺩ ﻭﺠﺩ ﺇﺠﺭﺍﺀ ﺘﻡ ﻝﻘﺩ
 ﺃﻥ ﻴﺒﺭﻫﻥ ﻋﻠﻰ ﻭﻫﺫﺍ HCI ﻭ ﺍل PSUﺍﻷﻤﺭﻴﻜﻲ  ﺍﻷﺩﻭﻴﺔﺍﻝﻔﺤﻭﺼﺎﺕ ﺍﻝﻤﻁﻠﻭﺒﺔ ﺤﺴﺏ ﻗﻭﺍﻨﻴﻥ ﺩﺴﺘﻭﺭ 
  . K.S.Aﺍﻝﻤﻭﺠﻭﺩﺓ ﻓﻲ ﻤﺴﺘﺤﻀﺭ ﺍل ﻭﻤﻌﺎ ﻤﺠﺘﻤﻌﺔ ﺍﻝﻁﺭﻴﻘﺔ ﺼﺎﻝﺤﺔ ﻝﺘﺤﻠﻴل ﺍﻝﻤﺭﻜﺒﺎﺕ ﺍﻝﺜﻼﺜﺔ 
ﺎ ﺘﻤﺘﺎﺯ ﺒﺎﻝﻜﻔـﺎﺀﺓ ﺍﻝﻌﺎﻝﻴـﺔ  ﻗﻠﺔ ﺍﻝﺘﻜﻠﻔﺔ ﺍﻝﻼﺯﻤﺔ ﻝﺘﺤﻠﻴل ﺍﻝﺩﻭﺍﺀ، ﻜﻤ  ﻭ ﺘﻤﺘﺎﺯ ﺍﻝﻁﺭﻴﻘﺔ ﺍﻝﻤﻁﻭﺭﺓ ﺒﺎﻝﺴﺭﻋﺔ 
 ﺍﻝﻤﺼﻨﻊ ﻤﻥ ﻗﺒل ﺸﺭﻜﺔ ﺩﺍﺭ ﺍﻝﺸﻔﺎﺀ K.S.Aﻋﻨﺩ ﺘﻁﺒﻴﻕ ﺍﻝﻁﺭﻴﻘﺔ ﺍﻝﺠﺩﻴﺩﺓ ﻋﻠﻰ ﻤﺴﺘﺤﻀﺭ  ﻭ ﻭﺍﻻﻨﺘﻘﺎﺌﻴﺔ
  (.ﺍﻝﻤﻭﺍﺩ ﺍﻝﻤﻀﺎﻓﺔ) ﻤﻊ ﺍﻝﺴﻭﺍﻍ ﺃﻭ ﻜل ﺍﻝﻤﺭﻜﺒﺎﺕ ﺍﻝﻔﻌﺎﻝﺔ ﻻ ﺘﺘﺩﺍﺨل ﻤﻊ ﺒﻌﻀﻬﺎ ﺃﻥ ﻝﻸﺩﻭﻴﺔ ﻭﺠﺩ
  
 ﻤـﻥ ﻗﺒـل ﻭﺯﺍﺭﺓ ﺍﻝـﺼﺤﺔ ﻭﺭﺓ  ﺍﻝﻤﻁ  ـ ﺍﻝﺠﺩﻴـﺩﻩ  ﺍﻻﻝﻴﺔ ﻫﺫﺍ ﻭﺴﻴﺘﻡ ﺘﻘﺩﻴﻡ ﻁﻠﺏ ﺍﻋﺘﻤﺎﺩ ﻝﻬﺫﻩ ﺍﻝﻁﺭﻴﻘﺔ 
  .ﺍﻝﻔﻠﺴﻁﻴﻨﻴﺔ ﻗﺭﻴﺒﺎ
  
